Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU) | Clínica e Investigación en Arteriosclerosis (English Edition)

array:23 ["pii" => "S2529912320300632" "issn" => "25299123" "doi" => "10.1016/j.artere.2020.02.004" "estado" => "S300" "fechaPublicacion" => "2020-09-01" "aid" => "528" "copyrightAnyo" => "2020" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Clin Investig Arterioscler. 2020;32:183-92" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:20 [ "pii" => "S0214916820300243" "issn" => "02149168" "doi" => "10.1016/j.arteri.2020.02.003" "estado" => "S300" "fechaPublicacion" => "2020-09-01" "aid" => "528" "copyright" => "The Authors" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Clin Invest Arterioscl. 2020;32:183-92" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "Original" "titulo" => "Perfil clínico de los pacientes tratados con evolocumab en unidades de lípidos/medicina interna en España. Estudio observacional (RETOSS-IMU)" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "183" "paginaFinal" => "192" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU)" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 960 "Ancho" => 2504 "Tamanyo" => 161644 ] ] "descripcion" => array:1 [ "es" => "Esquema de la población de estudio. *Un paciente podía no ser incluido por más de un motivo. Criterios de inclusión (CI): 1. Adultos (≥18años) en el momento de inicio del tratamiento con evolocumab. 2. Haber iniciado tratamiento con evolocumab según el criterio médico, con independencia del protocolo del estudio, entre el 1 de febrero de 2016 y el 31 de julio de 2017. 3. Haber recibido al menos una dosis de evolocumab (según criterio médico) por un especialista en una unidad de medicina interna en España. 4. Disponer de al menos una determinación de cLDL dentro de las 12semanas anteriores al inicio de evolocumab (último valor disponible 12semanas previas). Criterios de exclusión (CE): 1. Haber participado en un estudio con un inhibidor de PCSK9 en las 12 semanas previas al inicio del tratamiento con evolocumab. 2. Haber recibido un inhibidor de PCSK9 en las 12semanas previas al inicio del tratamiento con evolocumab. 3. Haber participado en un estudio clínico durante el periodo observacional retrospectivo, es decir, 12semanas antes del inicio del tratamiento con evolocumab o hasta 12semanas después de su inicio." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Lluís Masana, José López Miranda, Fernando Civeira, Leonardo Reinares, Carlos Guijarro, Núria Plana, Rafael Cuenca, Demetrio Sánchez, José Luis Hernández, Raimundo Andrés, Agustín Blanco, Santiago Villamayor" "autores" => array:12 [ 0 => array:2 [ "nombre" => "Lluís" "apellidos" => "Masana" ] 1 => array:2 [ "nombre" => "José" "apellidos" => "López Miranda" ] 2 => array:2 [ "nombre" => "Fernando" "apellidos" => "Civeira" ] 3 => array:2 [ "nombre" => "Leonardo" "apellidos" => "Reinares" ] 4 => array:2 [ "nombre" => "Carlos" "apellidos" => "Guijarro" ] 5 => array:2 [ "nombre" => "Núria" "apellidos" => "Plana" ] 6 => array:2 [ "nombre" => "Rafael" "apellidos" => "Cuenca" ] 7 => array:2 [ "nombre" => "Demetrio" "apellidos" => "Sánchez" ] 8 => array:2 [ "nombre" => "José Luis" "apellidos" => "Hernández" ] 9 => array:2 [ "nombre" => "Raimundo" "apellidos" => "Andrés" ] 10 => array:2 [ "nombre" => "Agustín" "apellidos" => "Blanco" ] 11 => array:2 [ "nombre" => "Santiago" "apellidos" => "Villamayor" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2529912320300632" "doi" => "10.1016/j.artere.2020.02.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912320300632?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0214916820300243?idApp=UINPBA00004N" "url" => "/02149168/0000003200000005/v1_202010040619/S0214916820300243/v1_202010040619/es/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S2529912320300644" "issn" => "25299123" "doi" => "10.1016/j.artere.2020.03.006" "estado" => "S300" "fechaPublicacion" => "2020-09-01" "aid" => "530" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Clin Investig Arterioscler. 2020;32:193-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Original" "titulo" => "Effect of clopidogrel vs. aspirin on pro-atherosclerotic NLRP1 inflammasome expression in endothelial cells. ECLOAS study" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "193" "paginaFinal" => "199" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Efecto del clopidogrel vs. aspirina en la función de la expresión del inflamasoma proaterosclerótico NLRP1 en células endoteliales. Estudio ECLOAS" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 696 "Ancho" => 3173 "Tamanyo" => 150621 ] ] "descripcion" => array:1 [ "en" => "Study phase order." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Silvia Bleda, Joaquin de Haro, Isabel Sánchez, Ilsem Laime, Francisco Acin" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Silvia" "apellidos" => "Bleda" ] 1 => array:2 [ "nombre" => "Joaquin" "apellidos" => "de Haro" ] 2 => array:2 [ "nombre" => "Isabel" "apellidos" => "Sánchez" ] 3 => array:2 [ "nombre" => "Ilsem" "apellidos" => "Laime" ] 4 => array:2 [ "nombre" => "Francisco" "apellidos" => "Acin" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0214916820300267" "doi" => "10.1016/j.arteri.2020.03.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0214916820300267?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912320300644?idApp=UINPBA00004N" "url" => "/25299123/0000003200000005/v3_202102250927/S2529912320300644/v3_202102250927/en/main.assets" ] "en" => array:21 [ "idiomaDefecto" => true "cabecera" => "Original article" "titulo" => "Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU)" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "183" "paginaFinal" => "192" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Lluís Masana, José López Miranda, Fernando Civeira, Leonardo Reinares, Carlos Guijarro, Núria Plana, Rafael Cuenca, Demetrio Sánchez, José Luis Hernández, Raimundo Andrés, Agustín Blanco, Santiago Villamayor" "autores" => array:12 [ 0 => array:4 [ "nombre" => "Lluís" "apellidos" => "Masana" "email" => array:1 [ 0 => "luis.masana@urv.cat" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "José" "apellidos" => "López Miranda" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "Fernando" "apellidos" => "Civeira" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "Leonardo" "apellidos" => "Reinares" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "d" "identificador" => "aff0020" ] ] ] 4 => array:3 [ "nombre" => "Carlos" "apellidos" => "Guijarro" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "e" "identificador" => "aff0025" ] ] ] 5 => array:3 [ "nombre" => "Núria" "apellidos" => "Plana" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 6 => array:3 [ "nombre" => "Rafael" "apellidos" => "Cuenca" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "f" "identificador" => "aff0030" ] ] ] 7 => array:3 [ "nombre" => "Demetrio" "apellidos" => "Sánchez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "g" "identificador" => "aff0035" ] ] ] 8 => array:3 [ "nombre" => "José Luis" "apellidos" => "Hernández" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "h" "identificador" => "aff0040" ] ] ] 9 => array:3 [ "nombre" => "Raimundo" "apellidos" => "Andrés" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "i" "identificador" => "aff0045" ] ] ] 10 => array:3 [ "nombre" => "Agustín" "apellidos" => "Blanco" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "j" "identificador" => "aff0050" ] ] ] 11 => array:3 [ "nombre" => "Santiago" "apellidos" => "Villamayor" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "k" "identificador" => "aff0055" ] ] ] ] "afiliaciones" => array:11 [ 0 => array:3 [ "entidad" => "Servicio de Medicina Interna, Hospital Universitario Sant Joan, IISPV, CIBERDEM, Reus, Tarragona, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Medicina Interna, Hospital Universitario Reina Sofía, IMIBIC, Universidad de Córdoba, CIBEROBN, Córdoba, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Servicio de Medicina Interna, Hospital Universitario Miguel Servet, IIS Aragón, CIBERCV, Universidad de Zaragoza, Zaragoza, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Servicio de Medicina Interna, Hospital Clínico San Carlos, Madrid, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Servicio de Medicina Interna, Hospital Universitario Fundación Alcorcón, Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Servicio de Medicina Interna, Hospital Alto Guadalquivir, Andújar, Jaén, Spain" "etiqueta" => "f" "identificador" => "aff0030" ] 6 => array:3 [ "entidad" => "Servicio de Medicina Interna, Hospital Nuestra Señora de Sonsoles, Ávila, Spain" "etiqueta" => "g" "identificador" => "aff0035" ] 7 => array:3 [ "entidad" => "Unidad de Lípidos y Riesgo Vascular, Servicio de Medicina Interna, Hospital Universitario Marqués de Valdecilla-IDIVAL. Santander. Universidad de Cantabria, Santander, Spain" "etiqueta" => "h" "identificador" => "aff0040" ] 8 => array:3 [ "entidad" => "Servicio de Medicina Interna, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain" "etiqueta" => "i" "identificador" => "aff0045" ] 9 => array:3 [ "entidad" => "Servicio de Medicina Interna, Hospital Universitario 12 de Octubre, Madrid, Spain" "etiqueta" => "j" "identificador" => "aff0050" ] 10 => array:3 [ "entidad" => "Departamento Médico, Amgen S.A., Barcelona, Spain" "etiqueta" => "k" "identificador" => "aff0055" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Perfil clínico de los pacientes tratados con evolocumab en unidades de lípidos/medicina interna en España. Estudio observacional (RETOSS-IMU)" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1757 "Ancho" => 2098 "Tamanyo" => 261431 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "History and cardiovascular risk factors. AHT: arterial hypertension; CAD: carotid arteriosclerotic disease; CD: cerebrovascular disease; CI: cardiac insufficiency; CV: cardiovascular; CVE: cardiovascular event; DM2: type 2 diabetes mellitus; FH: familial hypercholesterolaemia; He: heterozygote; Ho: homozygote; IMEST: myocardial infarct with raised ST segment; MI: myocardial infarct; Neph: nephropathy; PAD: peripheral arterial disease." ] ] ] "textoCompleto" => "IntroductionLow density lipoprotein-vehiculated cholesterol (cLDL) is a causal factor of cardiovascular arteriosclerotic disease (CVAD),<a class="elsevierStyleCrossRef" href="#bib0005">1</a> which originates a high level of morbimortality in our population.<a class="elsevierStyleCrossRef" href="#bib0010">2</a> As a whole, the set of cardiovascular diseases (CVD) cause approximately one of every three deaths in Spain, slightly more so for women than men.<a class="elsevierStyleCrossRefs" href="#bib0015">3,4</a> Treatment with hypocholesterolemiants has helped to reduce cardiovascular (CV) mortality.<a class="elsevierStyleCrossRef" href="#bib0025">5</a> More specifically, the use of statins (which became widespread in the final decade of the previous century) has given rise to an improved prognosis for CVAD. In the past 30 years, several controlled and randomised studies have supplied very solid scientific evidence for the benefit of hypocholesterolemiant treatment in case of cardiovascular risk (CVR).<a class="elsevierStyleCrossRefs" href="#bib0005">1,5</a>The development and clinical availability of PCSK9 inhibitors (PCSK9i) have led to a major advance in the management of hypercholesterolaemia. Evolocumab in particular has shown in multiple phase 2 and 3 clinical trials following its pharmacological development that it reduces cLDL by an average of more than 60%, regardless of the basal hypolipemiant treatment.<a class="elsevierStyleCrossRef" href="#bib0030">6</a> In the FOURIER study, which included more than 27,500 patients with cerebral and peripheral atheramatous vascular cardiac disease, evolocumab reduced the number of events significantly over a period of 2.2 years, confirming that the fall in cLDL induced by the use of evolocumab leads to a lower risk of CV complications.<a class="elsevierStyleCrossRef" href="#bib0035">7</a> These results are fully compatible with those foreseen by the Cholesterol Treatment Trialist Collaboration (CTTC).<a class="elsevierStyleCrossRef" href="#bib0040">8</a> Similar data were obtained in the ODYSSEY OUTCOMES study, which used alirocumab<a class="elsevierStyleCrossRef" href="#bib0045">9</a> in patients with recent acute coronary syndrome. Likewise, the SPIRE studies with bococizumab<a class="elsevierStyleCrossRef" href="#bib0050">10</a> gave similar results, although they were interrupted due to the loss of efficacy associated with the development of anti-bococizumab antibodies. The efficacy of the PCSK9i in preventing CV is in line with their hypolipemiant effect and the duration of treatment, according to the results of the CTTC. In the FOURIER study the patients treated with evolocumab attained average cLDL concentrations of 30 mg/dl, so that it also showed that lower figures than those obtained in previous studies were associated with a greater clinical benefit without increased side effects. These results show that in the prevention of CV the lower the cLDL achieved the better, without to data having been able to set a minimum level of cLDL at which this benefit attenuates or disappears.<a class="elsevierStyleCrossRef" href="#bib0055">11</a>In spite of the robust scientific evidence about the benefits of reducing cLDL levels to improve the prognosis of patients with high CVR, very few of them attain their therapeutic objectives. Recent fifth edition EUROASPIRE<a class="elsevierStyleCrossRef" href="#bib0060">12</a> registry data show that 71% of the patients who have suffered a coronary event do not achieve the target cLDL level below 70 mg/dl, and in 37% of cases they have levels above 100 mg/dl. Additionally, hypolipemiant treatment in patients with familial hypercholesterolaemia (FH) is a long way from achieving its therapeutic objectives, even in patients followed-up in specialised lipid units.<a class="elsevierStyleCrossRef" href="#bib0065">13</a> The beneficial effects of evolocumab have been demonstrated in population groups at high and very high CVR, achieving very high percentages of patients who attained their therapeutic objectives and even achieved lower figures, associated with greater clinical benefit.In spite of the unquestionable hypolipemient efficacy of the PCSK9i drugs, their prescription has been restricted in Spain due to a supposedly better cost-benefit balance. It is only dispensed in hospitals and its use has been restricted to patients with secondary prevention, or those with FH and cLDL levels higher than 100 mg/dl following treatment with high intensity statins or with the maximum tolerated dose of the same. Additionally, these indications have been modulated by scientific societies such as the Sociedad Española de Arteriosclerosis (SEA). In 2016<a class="elsevierStyleCrossRef" href="#bib0070">14</a> this society issued recommendations that were recently updated on the basis of new scientific evidence that shows the efficacy of PCSK9i drugs in reducing CV events in different groups of patients.<a class="elsevierStyleCrossRef" href="#bib0075">15</a> The European Medicines Agency recently approved the indication for PCSK9i to reduce CV complications, over and above simply reducing cholesterol, although the Spanish Medicines Agency has not yet updated the report on therapeutic positioning.<a class="elsevierStyleCrossRefs" href="#bib0080">16–19</a>The chief aim of this study was to evaluate which type of patients have been treated with evolocumab in the first phase of its clinical availability, in the internal medicine departments that most lipid units in Spain belong to, and its hypolipemiant efficacy within this context.Patients and methodsThis multicentre, retrospective and observational study reviewed the clinical histories of patients who had received evolocumab as part of the usual clinical treatment of hyperlipidaemia in a lipids unit /internal medicine department in Spain. Patients aged ≥ 18 years were included who had started treatment with evolocumab prescribed by a doctor in a lipids unit /internal medicine department (regardless of study protocol) from 1 February 2016 to 31 July 2017, who had received at least one dose of evolocumab and who had at least one determination of cLDL within the 12 weeks prior to the start of treatment with evolocumab. Patients who had taken part in a study or had received treatment with a PCSK9i in the 12 previous weeks and/or who had taken part in a clinical trial during the study period were excluded. 20 hospitals took part based on their geographical distribution and level of care.The protocol was approved by an ethics committee in each hospital, and all of the patients signed the informed consent document. Clinical data were recorded anonymously from 12 weeks prior to the start of treatment with evolocumab until 12 ± 4 weeks after this start. The last analytical parameters measured within the 12 weeks prior to starting treatment with evolocumab were considered to be basal values.The indications for starting treatment with evolocumab were recorded: the presence of FH and/or CVD established in the 12 weeks prior to starting the study. The main efficacy variable measured the variation between the previous cLDL levels (during the previous 12 weeks) and subsequent ones (the final determination during the following 12 weeks) after commencing with evolocumab. The following variables were also recorded: age, sex, professional situation, weight, height and body mass index at the start of treatment with evolocumab, family medical history (FH or any other dyslipidaemia, death due to a CV event, diabetes mellitus or hypertension), personal CVAD (ischemic cardiopathy, cerebrovascular accident, peripheral arteriopathy), a personal history of dyslipidaemia (FH, combined familial hyperlipidaemia, other types of hypercholesterolaemia and mixed or combined hyperlipidaemia), diabetes mellitus, hypertension, a history of chronic nephropathy, liver failure, hypothyroidism and smoking. Their previous analytical parameters were determined (the last available figure in the 12 weeks prior to starting treatment with evolocumab and the values subsequent to starting treatment available in the patient’s clinical history and corresponding to the planned follow-up visits according to clinical practice): lipid profile (total cholesterol, cLDL, cHDL, triglycerides, non-HDL cholesterol and lipoprotein (a) [Lp(a)]. Additionally, analysis took place to detect whether the therapeutic objectives set by the clinical guides in force at the time (ESC/EAS 2016) for managing hyperlipidaemia had been achieved.<a class="elsevierStyleCrossRef" href="#bib0100">20</a>Finally, the use of other hypolipemient treatments was recorded, together with any statin intolerance before starting treatment with evolocumab and all of the hypolipemient treatment in the 12 subsequent weeks. Statin intolerance was defined as intolerance to an initial statin at maximum tolerable dose and to a second statin at any dose with an adverse effect attributed to the drug that was resolved when it was withdrawn.In an exploratory way the hospital and speciality of the doctor who referred the patient to the hospital internal medicine department to start treatment with evolocumab were also determined, together with the number of planned visits in the following months during the first year of treatment and other medical specialities consulted by the patients in the hospital during the study, the hospital in which treatment with evolocumab started and the speciality of the doctor who diagnosed hypercholesterolaemia.Statistical analysisA descriptive statistical analysis was performed for all of the variables. The quantitative variables were described using central tendency and dispersion measurements (average, standard deviation [SD], minimum, 25% quartile [Q1], median, 75% quartile [Q3] and maximum for non-parametric variables). For qualitative variables frequency tables and parentages over the total number of responses that could be evaluated were used. In all cases 95% confidence intervals were used (CI 95%).The demographic and clinical variables, medical family and personal histories, CVR factors and lipid profile evolution during the study were compared between the following patient subgroups: presence and type of FH, presence and type of diabetes, statin intolerance, basal cLDL ranges, primary and secondary prevention and age groups.The change in cLDL levels was compared in different visits versus basal levels using the Student t-test for repeated measurements. Levels < .05 were considered to be statistically significant.An analysis was also carried out of the cLDL levels at the last available measurement after starting treatment with evolocumab.All of the statistical analyses were performed using version 9.4 of the SAS® System for Windows.ResultsA total of 157 patients were recruited, of whom 21 were excluded as they did not meet the selection criteria. The most common reason for exclusion (71.4% of the patients) was that the date their final determination of cLDL was obtained was before the pre-established margin of 12 weeks (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). Finally, 136 patients were included in the evaluation.<elsevierMultimedia ident="fig0005"></elsevierMultimedia>The average age (SD) of these 136 patients was 56.6 (11.5) years. 64.0% were men, and their average body mass index was 29.4 (4,8) kg/m2. The average cLDL level (SD) before starting treatment with evolocumab was 169.1 (56.6) mg/dl. Their sociodemographic, anthropometric and clinical data are shown in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>. 75.0% of the patients included were diagnosed as FH, of whom 4 were homozygotic. 51.0% of the patients with FH had previous CVAD, and 36.0% of all the patients were considered to be statin intolerant. These were mainly intolerant of atorvastatin (81.6% of the intolerant patients), followed by rosuvastatin (57.1%) and simvastatin (38.8%). The median(Q1-Q3) time from detection of intolerance was 4.0 (2.0-7.9) years.<elsevierMultimedia ident="tbl0005"></elsevierMultimedia>61.1% of the patients had an established history of CVAD. Their histories and basal CVR factors are shown in <a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>.<elsevierMultimedia ident="fig0010"></elsevierMultimedia>It should be underlined that 75.8% of the patients had cLDL levels higher than 130 mg/dl, while in 46.4% it was higher than 160 mg/dl and approximately one of every four patients (26.5%) had levels above 190 mg/dl (<a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>A). Their highest basal cLDL levels generally corresponded to patients with FH in primary prevention, and they were lower in patients without FH in secondary prevention. The basal levels of cLDL according to the clinical characteristics of the patients are shown in <a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>B.<elsevierMultimedia ident="fig0015"></elsevierMultimedia>At the start of treatment with evolocumab 61.0% of the patients were taking high intensity statins, 60.3% were taking ezetimibe and 49.3% were taking both. The median (Q1-Q3) duration of treatment prior to starting with evolocumab was 3.9 (1.5-7.0) years for the high intensity statins and 4.7 (1.1-10.0) years for ezetimibe. <a class="elsevierStyleCrossRef" href="#fig0020">Fig. 4</a> shows statin treatment intensity distribution (A) and with ezetimibe (B) before starting treatment with evolocumab.<elsevierMultimedia ident="fig0020"></elsevierMultimedia>Treatment with evolocumab produced an average fall of cLDL at 12 weeks of 55.7%, achieving average values of 79.6 mg/dl. More specifically, 26.9% of the patients attained cLDL levels below 50 mg/dl, 53.8% reached levels below 70 mg/dl and 74.4% reached levels below 100 mg/dl.The results of the analysis of cLDL levels in patients who had data for their last observation after the start of treatment with evolocumab (n = 110) showed an average fall from basal level of 60.8%, achieving an average value of 74.3 mg/dl after a median follow-up time of 10.9 weeks.Likewise, evolocumab also induced falls in non-HDL cholesterol (an average reduction of 49.9%), without finding a significant change in cHDL levels. There were too few patients with Lp(a) determinations after starting treatment to enable evaluation of the same.Due to the inclusion criteria, no patient was at target cLDL levels according to their clinical condition. The therapeutic objectives in the study populations (defined as cLDL levels < 70 mg/dl or cLDL < 100 mg/dl by the 2016 ESC/EAS guides) depending on the CVR situation were achieved by 51.9% of the patients with FH and a CV event, 61.3% of patients with a CV event and no FH and 48.0% of the patients with FH and no previous CV event (<a class="elsevierStyleCrossRef" href="#fig0025">Fig. 5</a>).<elsevierMultimedia ident="fig0025"></elsevierMultimedia>Basic hypolipemiant treatment was kept stable in the majority of the patients, and only 10.8% suspended their treatment with ezetimibe. The treatment with evolocumab was not suspended in any patient in the studied population, and only one patient increased the interval between doses due to discomfort at the point of injection.The majority of the patients included in the study were already being managed by lipid units/internal medicine (68.4%), while 19.1% were detected by primary care and 8.1% were detected by cardiology and referred to the said units. Treatment with evolocumab involved an average of two visits per year for control and renewal of the prescription.DiscussionThis work describes the clinical characteristics of the patients who were prescribed treatment with evolocumab in specialised lipid and CVR units in internal medicine departments in Spain during the initial phase of product commercialisation. As may be expected, the majority of the patients treated in these units had FH (75% of the sample), bases on two criteria: a very high level of cLDL in the case of primary prevention, or patients who had already suffered an event (51% of the patients with FH). The second group is composed of patients in secondary prevention without FH. As a whole, 61% of all treatments were prescribed for patients with established CVAD, and for 38% of patients with established CVAD and FH. The fact that the work centred on internal medicine units, the majority of which have SEA accredited lipid units, explains the high proportion of patients with FH. Moreover, as the study took place at the start of availability of the drug, many patients were included who had been monitored historically by the said units who had not attained their objectives and for whom no effective alternative treatment had been available. A clear sign of this is the high percentage of statin-intolerant patients who were included (36%). It also has to be said that 39% of the patients were not receiving high intensity statins (practically all of them were statin-intolerant), as well as the high percentage of patients treated with ezetimibe (60%). It is clear that patients in secondary prevention without FH represent a more numerous group of candidates for therapy with evolocumab. Nevertheless, and unlike the situation with FH, which is usually controlled and followed up in specialised dyslipedaemia units, subjects who have suffered an ischemic CV event are treated by cardiology, neurology or vascular surgery units. Subsequently, these patients are often followed up by primary care doctors. This circumstance may lead to a not insignificant group of these patients not receiving a suitable prescription for PCSK9i, as this drug is dispensed in hospital. Cardiac rehabilitation units, or otherwise lipid, vascular risk or secondary prevention units, play an especially important role, as these are units that determine the moment when PCSK9i is indicated.It is striking that the average cLDL level at the moment of indication (169 mg/dl) was clearly above the authorised level for financing of the drug, which stands at 100 mg/dl, showing that the patients who started treatment clearly fulfilled the indications of the therapeutic positioning report. The fact that the starting point in this cohort is clearly above the recommended treatment thresholds, with almost half of the subjects with cLDL levels > 160 mg/dl and 26% > 190 mg/dl, may indicate that the first patients who were prescribed evolocumab were patients who had exhausted all of the other therapeutic options in attempting to achieve their cLDL objectives. It also has to be taken into account that the majority of this cohort are patients with FH and, therefore, with very high basal cLDL levels. In fact, the basal cLDL of the patients without FH in secondary prevention was clearly lower. Additionally, given the administrative barriers against prescribing PCSK9i, it is probable that in this initial phase patients with an unquestionable therapeutic indication were selected.The SEA recently published its latest recommendations for the use of PCSK9i, where it clearly identified the patient profiles which will gain the greatest clinical benefit with these therapies.15 This may imply the indication of these drugs at lower cLDL levels in patients at especially high risk.This study in the context of habitual clinical practice confirms the hypolipemiant efficacy of evolocumab, which produced an average fall in initial average cLDL concentrations of 56%, a similar result to that of the clinical trials. In this way, the average levels of cLDL fell below 80 mg/dl in spite of their high starting point (only 2.2% of the patients had basal levels lower than 100 mg/dl). Additionally, 54% attained cLDL levels below 70 mg/dl, and 27% attained levels below 50 mg/dl. One highly important datum is the high percentage of patients who attained their therapeutic objectives according to whether or not they had a previous CV event and/or FH. According to the inclusion criteria, no patient had complied with their therapeutic cLDL objectives; the majority of them were a long way from doing so. In spite of this starting point, approximately half of the patients with FH (51.9% with a CV event and 48% without a previous CV event) and 61% of the ones with a CV event without FH achieved their respective therapeutic objectives as set in the 2016 ESC/EAS guides20 after 12 weeks of treatment with evolocumab.However, these treatment guides have been updated very recently, and they now specify much stricter therapeutic objectives for the control of cLDL. Patients with CVAD (with or without FH) should attain cLDL concentrations below 55 mg/dl, while in patients with FH without CVAD the therapeutic objective is to achieve cLDL levels below 70 mg/dl. Taking these new objectives into account, and in spite of the severity of the patients who started treatment with evolocumab at the start of its commercialisation, 30.8% and 41.9% of the patients with FH and a CV event or a CV event without FH obtained levels below 50 mg/dl, respectively. On the other hand, of the patients with FH without a previous CV event, 34% of them obtained levels below 70 mg/dl, indicating that at least one of every 3 patients would accomplish the stricter new objectives in the 2019 ESC/EAS guides.<a class="elsevierStyleCrossRef" href="#bib0105">21</a>These data show the utility of treatment with evolocumab in achieving therapeutic objectives in high risk patients. Taking into account the recent data from the EUROASPIRE 512 registry, the possibility of increasing hypercholesterolaemia control to this degree in secondary prevention by using evolocumab is unprecedented. Moreover, the results of the FOURIER study, in which more than 87% of the patients were found to achieve cLDL levels ≤ 70 mg/dl after 48 weeks of treatment with evolocumab, also emphasises the usefulness of this drug in achieving therapeutic targets.<a class="elsevierStyleCrossRef" href="#bib0035">7</a>Although the objectives of this study did not include monitoring pharmacological safety, the high level of adherence to the treatment should be mentioned, given that only one patient discontinued therapy with evolocumab temporarily.This study has certain limitations: it is a retrospective study limited in observation time, so that it cannot offer data on the impact of the therapy over the longer term. The sample size is small, too, although it is based on strict selection criteria and exhaustive quality control of the data obtained. On the other hand, it centres on lipid units/internal medicine departments, with their particularities: a high frequency of severe dyslipidaemia and statin intolerance. It is probable that the power of evolocumab to attain therapeutic objectives in other contexts would be even greater. In connection with other lipid parameters such as Lp(a), given the observational nature of the study it was not possible to have sufficiently large samples at different points of the study to be able to evaluate its effects.There are other analyses of clinical experience with evolocumab in Spain, such as the twin study of this one, the RETOSS-CARDIO study which was undertaken in cardiology units. The efficacy of evolocumab was comparable, as it gave rise to significant falls in cLDL of 58%, although with differences in population type, with more patients with CVD and without FH.<a class="elsevierStyleCrossRef" href="#bib0110">22</a> Cordero and his collaborators recently published a retrospective multicentre analysis of the use of PCSK9i in 5 Spanish hospitals. They found significant falls in cLDL in approximately 68% and of 41% in comparison with the basal level after using evolocumab and alirocumab, respectively.<a class="elsevierStyleCrossRef" href="#bib0115">23</a>This is the first study to report on the clinical profile of the patients treated with evolocumab in lipid units /internal medicine departments in Spain. In this first phase of availability of the therapy patients have been included with a marked diagnosis of severity, very high CVR and very high cLDL levels. Evolocumab has to offer clinical benefits to a population with less extreme indications and therapeutic financing that the one covered by this work, in agreement with the data of the scientific evidence now available.FinancingThis study was financed by Amgen through an unrestricted subvention.Conflict of interestsL. Masana has received fees for conferences or scientific consultancy services from Amgen, Sanofi-Regeneron, Mylan, MSD, Daiichi-Sankyo, Danone and Servier.J. López Miranda has received fees for conferences or scientific consultancy services from Amgen, Sanofi-Regeneron, Ferrer, Esteve and Boeringher.F. Civeira has received fees for conferences or scientific consultancy services from Amgen, Sanofi-Regeneron, MSD and Ferrer.L. Reinares participated in the ODYSSEY study as head researcher in the Hospital Clínico.C. Guijarro has received fees for talks, training and consultancy from Amgen, Ferrer, MSD, Pfizer and Sanofi.N. Plana has received fees for conferences from Amgen, Sanofi-Regeneron and MSD.R. Cuenca has received fees for conferences from Amgen and Esteve.J.L. Hernández has received fees for talks or conferences and courses from Amgen, MSD, Sanofi and Esteve, together with research grants from Amgen.R. Andrés has received fees for talks or conferences from Amgen and Sanofi.A. Blanco has received fees for conferences or scientific consultancy services from Amgen, Sanofi-Regeneron and Servier.S. Villamayor is an Amgen S.A. employee.D. Sánchez has no conflict of interests to declare." "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:3 [ "identificador" => "xres1471491" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Objective" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1340093" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres1471492" "titulo" => "Resumen" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivo" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1340092" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Patients and methods" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Statistical analysis" ] ] ] 6 => array:2 [ "identificador" => "sec0020" "titulo" => "Results" ] 7 => array:2 [ "identificador" => "sec0025" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0030" "titulo" => "Financing" ] 9 => array:2 [ "identificador" => "sec0035" "titulo" => "Conflict of interests" ] 10 => array:2 [ "identificador" => "xack515623" "titulo" => "Acknowledgements" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2019-11-28" "fechaAceptado" => "2020-02-24" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1340093" "palabras" => array:5 [ 0 => "Evolocumab" 1 => "Familial hypercholesterolaemia" 2 => "Arteriosclerotic cardiovascular disease" 3 => "LDL-C" 4 => "Lipid unit/internal medicine" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1340092" "palabras" => array:5 [ 0 => "Evolocumab" 1 => "Hipercolesterolemia familiar" 2 => "Enfermedad cardiovascular arteriosclerótica" 3 => "c-LDL" 4 => "Unidades de lípidos/medicina interna" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "ObjectiveTo describe the clinical characteristics, the reasons for initiating therapy, and the effects of treatment in the initial phase of evolocumab availability in Lipid/ Internal Medicine Units in Spain. MethodsRetrospective, observational study, based on the medical records of consecutive patients initiating treatment with evolocumab (from February 2016 to July 2017), in 20 Internal Medicine Units in Spain. A review was made of the demographic and clinical characteristics of the patients, the lipid lowering treatment, and the evolution of the lipid profiles between 12 weeks pre-initiation and 12 ± 4 weeks post-initiation of evolocumab. ResultsA total of 136 patients were analysed, of whom 64.0% were men, and the mean age (standard deviation, SD) was 56.6 (11.5) years. The large majority (75%) had familial hypercholesterolaemia (FH) (4 homozygous), and 51.0% of them had suffered at least one cardiovascular event. Atherosclerotic cardiovascular disease (ASCVD) was present in 61% of all patients. At initiation of evolocumab, 61.0% of the patients were taking high-intensity statins, and 60.3% were receiving ezetimibe. The mean (and SD) of LDL-c levels at initiation of evolocumab was 169.1 (56.6) mg/dL. The LDL-c was greater than 160 mg/dL in 46.4% of patients, and ≥190 mg/dL in 26.5%. During the observation period, evolocumab produced significant reductions in LDL-c of 55.7% (p < .0001), achieving mean values of 74.3 mg/dL. At week 12, more than half (53.8%) of patients achieved LDL-c levels <70 mg/dL, and 26.9% <50 mg/dL. ConclusionsIn the Lipid/Internal Medicine Units, evolocumab was mainly prescribed in patients with FH, with or without ASCVD. The initial use of evolocumab was in accordance with the guidelines of the Spanish Society of Arteriosclerosis (SEA) of 2016, with LDL-c levels being well above the recommended thresholds for treatment initiation. Evolocumab treatment in clinical practice reduced LDL-C levels by about 55%, a similar reduction to that reported in clinical trials. Most patients achieved LDL-c goals." "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Objective" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] "es" => array:3 [ "titulo" => "Resumen" "resumen" => "ObjetivoDescribir las características clínicas, las razones del inicio de la terapia y los efectos del tratamiento en la fase inicial de disponibilidad de evolocumab en las unidades de lípidos/medicina interna de España. MétodosEstudio retrospectivo, observacional, a partir de las historias clínicas de pacientes consecutivos que iniciaron tratamiento con evolocumab (de febrero 2016 a julio 2017), en 20 unidades de Medicina Interna en España. Se revisaron las características demográficas y clínicas de los pacientes, el tratamiento hipolipemiante y la evolución de los perfiles lipídicos entre 12 semanas antes y 12 ± 4 semanas después del inicio de evolocumab. ResultadosSe analizaron 136 pacientes: el 64,0% eran hombres, la edad media (desviación estándar, DE) fue de 56,6 (11,5) años. El 75,0% tenía hipercolesterolemia familiar (HF) (4 homocigotos) de los que el 51,0% habían sufrido al menos un evento cardiovascular (CV). El 61,0% del total de pacientes presentaban enfermedad cardiovascular aterosclerótica (ECVA). Al inicio de evolocumab, 61,0% de los pacientes tomaban estatinas de alta intensidad y el 60,3% estaban recibiendo ezetimiba. La media (DE) de los niveles de c-LDL al inicio de evolocumab fue de 169,1 (56,6) mg/dL. En 46,4% de los pacientes el c-LDL fue superior a 160 mg/dL y en el 26,5% ≥190 mg/dL. Durante el período de observación, evolocumab produjo reducciones significativas de c-LDL del 55,7% (p < 0,0001), alcanzando unos valores medios de 74,3 mg/dL. En la semana 12, el 53,8% de los pacientes alcanzó niveles de c-LDL <70 mg/dL y el 26,9% <50 mg/dL. ConclusionesEn las Unidades de Lípidos/Medicina Interna, evolocumab se prescribió predominantemente en pacientes con HF con o sin ECVA. El uso inicial de evolocumab se ajustó a las pautas de la Sociedad Española de Arteriosclerosis (SEA) de 2016, estando las concentraciones de c-LDL claramente por encima de los umbrales recomendados para inicio de tratamiento. El tratamiento con evolocumab en la práctica clínica redujo los niveles de cLDL en torno al 55%, cifra comparable a los ensayos clínicos permitiendo alcanzar los objetivos terapéuticos en la mayoría de los casos." "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivo" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "Please cite this article as: Masana L, López Miranda J, Civeira F, Reinares L, Guijarro C, Plana N et al. Perfil clínico de los pacientes tratados con evolocumab en unidades de lípidos/medicina interna en España. Estudio observacional (RETOSS-IMU). Clin Investig Arterioscler. 2020;32:183–192." ] ] "multimedia" => array:6 [ 0 => array:8 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 965 "Ancho" => 2507 "Tamanyo" => 117894 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Study population. *A patient may be excluded for more than one reason Inclusion criteria (IC): 1. Adults (≥ 18 years) at moment of starting treatment with evolocumab. 2. Who started treatment with evolocumab based on medical criteria, regardless of study protocol, from 1 February 2016 and 31 July 2017. 3. Who received at least one dose of evolocumab (based on medical criteria)from a specialist in an internal medicine unit in Spain. 4. With at least one available determination of cLDL in the 12 weeks prior to starting to receive evolocumab (last available level in the 12 previous weeks). Exclusion criteria (EC): 1. Having taken part in a study with a PCSK9 inhibitor in the 12 weeks before starting treatment with evolocumab. 2. Having received a PCSK9 inhibitor in the 12 weeks before starting treatment with evolocumab. 3. Having participated in a clinical trial during the retrospective observational period, i.e., 12 weeks before starting treatment with evolocumab or up to 12 weeks after it commenced." ] ] 1 => array:8 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1757 "Ancho" => 2098 "Tamanyo" => 261431 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "History and cardiovascular risk factors. AHT: arterial hypertension; CAD: carotid arteriosclerotic disease; CD: cerebrovascular disease; CI: cardiac insufficiency; CV: cardiovascular; CVE: cardiovascular event; DM2: type 2 diabetes mellitus; FH: familial hypercholesterolaemia; He: heterozygote; Ho: homozygote; IMEST: myocardial infarct with raised ST segment; MI: myocardial infarct; Neph: nephropathy; PAD: peripheral arterial disease." ] ] 2 => array:8 [ "identificador" => "fig0015" "etiqueta" => "Fig. 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 2327 "Ancho" => 2181 "Tamanyo" => 226321 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0015" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Basal cLDL levels prior to starting treatment with evolocumab. CVE: cardiovascular event; FH: familial hypercholesterolaemia." ] ] 3 => array:8 [ "identificador" => "fig0020" "etiqueta" => "Fig. 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 1173 "Ancho" => 2098 "Tamanyo" => 112328 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0020" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Intensity of treatment with statins (A) and with ezetimibe (B) before starting treatment with evolocumab." ] ] 4 => array:8 [ "identificador" => "fig0025" "etiqueta" => "Fig. 5" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr5.jpeg" "Alto" => 1160 "Ancho" => 2098 "Tamanyo" => 104849 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0025" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Patients who attained the therapeutic objective. CVE: cardiovascular event; FH: familial hypercholesterolaemia." ] ] 5 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0030" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "BMI: body mass index; CVE: cardiovascular event; FH: familial hypercholesterolaemia; SD: standard deviation." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Characteristics \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Patients evaluated<a class="elsevierStyleCrossRef" href="#tblfn0005">a</a> (n = 136) \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Age in years, average (SD) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">56.6 (11.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Male sex, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">87 (64.0) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Weight in kg, average (SD) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">81.1 (14.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">BMI (kg/m2), average (SD) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">29.4 (4.8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Professional situation, n (%)</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">In work \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">71 (52.2) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Retired \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">51 (37.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Others \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">14 (10.3) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Statin intolerance, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">49 (36.0) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">FH, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">102 (75.0) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Homozygotic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 (2.9) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Heterozygotic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">98 (72.1) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Patients in secondary prevention, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">83 (61.0%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Patients with FH and secondary prevention, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">52 (38.2%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">[0,1–2]</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">[0,1–2]Basal lipid determinations (mg/dl), average (SD)</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Total cholesterol \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">244.8 (62.9) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">LDL cholesterol \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">169.1 (56.6) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HDL cholesterol \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">50.7 (13.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Non-HDL cholesterol \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">189.7 (61.2) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Triglycerides \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">142.5 (82.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2532146.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "Including 3 patients who had no previous CVE and no FH." ] ] ] "descripcion" => array:1 [ "en" => "Sociodemographic, anthropometric and basal clinical characteristics." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:23 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B.A. Ference" 1 => "H.N. Ginsberg" 2 => "I. Graham" 3 => "K.K. Ray" 4 => "C.J. Packard" 5 => "E. Bruckert" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/ehx144" "Revista" => array:6 [ "tituloSerie" => "Eur Heart J." "fecha" => "2017" "volumen" => "38" "paginaInicial" => "2459" "paginaFinal" => "2472" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28444290" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Instituto Nacional de Estadística [Internet]. Defunciones según la Causa de Muerte 2016. [accessed 8 Apr 2019]. Available from: http://www.ine.es/jaxi/Tabla.htm?path=/t15/p417/a2016/l0/&file=01003.px&L=0.8." ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "European Heart Network. CVD Statistics [Internet]. [accessed 28 May 2019]. Available from: http://www.ehnheart.org/cvd-statistics.html." ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Contribuciones de la mortalidad cardiovascular a la esperanza de vida de la población española de 1980 a 2009" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "JM García-González" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.recesp.2013.05.014" "Revista" => array:6 [ "tituloSerie" => "Rev Esp Cardiol." "fecha" => "2013" "volumen" => "66" "paginaInicial" => "848" "paginaFinal" => "853" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24773991" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "P.R. Hebert" 1 => "J.M. Gaziano" 2 => "K.S. Chan" 3 => "C.H. Hennekens" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jama.1997.03550040069040" "Revista" => array:6 [ "tituloSerie" => "JAMA" "fecha" => "1997" "volumen" => "278" "paginaInicial" => "313" "paginaFinal" => "321" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9228438" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Sabatine" 1 => "R. Giugliano" 2 => "S. Wiviott" 3 => "F. Raal" 4 => "D. Blom" 5 => "J. Robinson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1500858" "Revista" => array:7 [ "tituloSerie" => "N Engl J Med" "fecha" => "2015" "volumen" => "372" "paginaInicial" => "1500" "paginaFinal" => "1509" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25773607" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0168827814005492" "estado" => "S300" "issn" => "01688278" ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Sabatine" 1 => "R. Giugliano" 2 => "A. Keech" 3 => "N. Honarpour" 4 => "S. Wiviott" 5 => "S. Murphy" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1615664" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2017" "volumen" => "376" "paginaInicial" => "1713" "paginaFinal" => "1722" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28304224" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Baigent" 1 => "A. Keech" 2 => "P. Kearney" 3 => "L. Blackwell" 4 => "G. Buck" 5 => "C. Pollicino" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(05)67394-1" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2005" "volumen" => "366" "paginaInicial" => "1267" "paginaFinal" => "1278" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16214597" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Schwartz" 1 => "P. Steg" 2 => "M. Szarek" 3 => "D. Bhatt" 4 => "V. Bittner" 5 => "R. Diaz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1801174" "Revista" => array:7 [ "tituloSerie" => "N Engl J Med" "fecha" => "2018" "volumen" => "379" "paginaInicial" => "2097" "paginaFinal" => "2107" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30403574" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0016508520303620" "estado" => "S300" "issn" => "00165085" ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Ridker" 1 => "J. Revkin" 2 => "P. Amarenco" 3 => "R. Brunell" 4 => "M. Curto" 5 => "F. Civeira" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1701488" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med." "fecha" => "2017" "volumen" => "376" "paginaInicial" => "1527" "paginaFinal" => "1539" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28304242" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Giugliano" 1 => "T. Pedersen" 2 => "J. Park" 3 => "Z. Gaciong" 4 => "R. Ceska" 5 => "K. Toth" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(17)32290-0" "Revista" => array:5 [ "tituloSerie" => "Lancet" "fecha" => "2017" "volumen" => "390" "paginaInicial" => "1962" "paginaFinal" => "1971" ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Kotseva" 1 => "G. De Backer" 2 => "D. De Bacquer" 3 => "L. Rydén" 4 => "A. Hoes" 5 => "D. Grobbee" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/2047487318825350" "Revista" => array:6 [ "tituloSerie" => "Eur J Prev Cardiol" "fecha" => "2019" "volumen" => "26" "paginaInicial" => "824" "paginaFinal" => "835" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30739508" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Consecución del objetivo terapéutico del colesterol de las lipoproteínas de baja densidad en las unidades de lípidos y riesgo vascular de la Sociedad Española de Arteriosclerosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J. Pedro-Botet" 1 => "J.M. Mostaza" 2 => "X. Pintó" 3 => "JR Banegas" 4 => "en nombre del grupo de investigadores EDICONDIS-ULISEA" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.arteri.2013.07.006" "Revista" => array:6 [ "tituloSerie" => "Clin Investig Arterioscler." "fecha" => "2013" "volumen" => "25" "paginaInicial" => "155" "paginaFinal" => "163" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24041476" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Documento de consenso de la Sociedad Española de Arteriosclerosis sobre las indicaciones de los inhibidores de la PCSK9" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Masana" 1 => "J. Acaso" 2 => "F. Civeira" 3 => "J. Pedro-Botet" 4 => "P. Valdivielso" 5 => "C. Guijarro" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.arteri.2016.02.001" "Revista" => array:5 [ "tituloSerie" => "Clin Invest Arterioscl." "fecha" => "2016" "volumen" => "28" "paginaInicial" => "164" "paginaFinal" => "165" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Indicaciones de los inhibidores de PCSK9 en la práctica clínica. Recomendaciones de la Sociedad Española de Arteriosclerosis (SEA), 2019" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.F. Ascaso" 1 => "F. Civeira" 2 => "C. Guijarro" 3 => "J. López Miranda" 4 => "L. Masana" 5 => "J.M. Mostaza" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.arteri.2019.04.002" "Revista" => array:5 [ "tituloSerie" => "Clin Invest Arterioscl." "fecha" => "2019" "volumen" => "31" "paginaInicial" => "128" "paginaFinal" => "139" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Agencia Española de Medicamentos y Productos Sanitarios [Internet]. Informe de Posicionamiento Terapéutico de evolocumab (Repatha®) en hipercolesterolemia. 2016 [accessed 19 Apr 2019]. Available from: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-evolocumab-repatha.pdf." ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Agencia Española de Medicamentos y Productos Sanitarios [Internet]. Informe de Posicionamiento Terapéutico de alirocumab (Praluent®) en hipercolesterolemia. 2016 [accessed 19 Apr 2019]. Available from: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-alirocumab-Praluent-hipercolesterolemia.pdf." ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "European Medicines Agency [Internet]. EMA/233126/2018. Committee for Medicinal Products for Human Use (CHMP). Assessment report: Repatha. 2018 [accessed 19 Apr 2019]. Available from: https://www.ema.europa.eu/en/documents/variation-report/repatha-h-c-3766-ii-0017-g-epar-assessment-report-variation_en.pdf." ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "European Medicines Agency [Internet]. EMA/CHMP/44606/2019. Committee for Medicinal Products for Human Use (CHMP). Summary of opinion (post authorisation): Praluent (alirocumab). 2019 [accessed 19 Apr 2019]. Available from: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-praluent-ii-42_en.pdf." ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "2016 ESC/EAS Guidelines for the Management of Dyslipidaemias" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.L. Catapano" 1 => "I. Graham" 2 => "G. De Backer" 3 => "O. Wiklund" 4 => "M.J. Chapman" 5 => "H. Drexel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/ehw272" "Revista" => array:7 [ "tituloSerie" => "Eur Heart J." "fecha" => "2016" "volumen" => "37" "paginaInicial" => "2999" "paginaFinal" => "3058" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27567407" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S2468125320300571" "estado" => "S300" "issn" => "24681253" ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Mach" 1 => "C. Baigent" 2 => "A.L. Catapano" 3 => "K.C. Koskinas" 4 => "M. Casula" 5 => "L. Badimon" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/ehz455" "Revista" => array:6 [ "tituloSerie" => "Eur Heart J" "fecha" => "2020" "volumen" => "41" "paginaInicial" => "111" "paginaFinal" => "188" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31504418" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Barrios V., Escobar C., Arrarte V., Roldán C. Primer registro nacional de evolocumab en la práctica clínica en unidades de cardiología en España. Estudio RETOSS-CARDIO. Rev Esp Cardiol [Internet]. [accessed 7 Feb 2020]; Available from: http://www.revespcardiol.org/es-primer-registro-nacional-evolocumab-practica-avance-S0300893219305536." ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Experiencia inicial en la práctica clínica con los inhibidores PCSK–9 para las indicaciones actuales de financiación en España | Revista Española de Cardiología [Internet]. [accessed 7 Feb 2020]. Available from: https://www.revespcardiol.org/es-experiencia-inicial-practica-clinica-con-articulo-S0300893219301629?." ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack515623" "titulo" => "Acknowledgements" "texto" => "We would like to thank the medical department of Amgen for the design of the study in collaboration with the national coordinator of the same and the main researchers (scientific committee) in each hospital.The manuscript was prepared by the scientific coordinator of the study and validated by the scientific committee, with the help of TFS S.L., which monitored the study, undertook the statistical analysis and revised the text of the manuscript." "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/25299123/0000003200000005/v3_202102250927/S2529912320300632/v3_202102250927/en/main.assets" "Apartado" => array:4 [ "identificador" => "64744" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Originals" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/25299123/0000003200000005/v3_202102250927/S2529912320300632/v3_202102250927/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912320300632?idApp=UINPBA00004N"]

Statistics

Original article

Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU)

Perfil clínico de los pacientes tratados con evolocumab en unidades de lípidos/medicina interna en España. Estudio observacional (RETOSS-IMU)

Lluís Masanaa,

Corresponding author

luis.masana@urv.cat

Corresponding author.

, José López Mirandab, Fernando Civeirac, Leonardo Reinaresd, Carlos Guijarroe, Núria Planaa, Rafael Cuencaf, Demetrio Sánchezg, José Luis Hernándezh, Raimundo Andrési, Agustín Blancoj, Santiago Villamayork

a Servicio de Medicina Interna, Hospital Universitario Sant Joan, IISPV, CIBERDEM, Reus, Tarragona, Spain

b Servicio de Medicina Interna, Hospital Universitario Reina Sofía, IMIBIC, Universidad de Córdoba, CIBEROBN, Córdoba, Spain

c Servicio de Medicina Interna, Hospital Universitario Miguel Servet, IIS Aragón, CIBERCV, Universidad de Zaragoza, Zaragoza, Spain

d Servicio de Medicina Interna, Hospital Clínico San Carlos, Madrid, Spain

e Servicio de Medicina Interna, Hospital Universitario Fundación Alcorcón, Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain

f Servicio de Medicina Interna, Hospital Alto Guadalquivir, Andújar, Jaén, Spain

g Servicio de Medicina Interna, Hospital Nuestra Señora de Sonsoles, Ávila, Spain

h Unidad de Lípidos y Riesgo Vascular, Servicio de Medicina Interna, Hospital Universitario Marqués de Valdecilla-IDIVAL. Santander. Universidad de Cantabria, Santander, Spain

i Servicio de Medicina Interna, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain

j Servicio de Medicina Interna, Hospital Universitario 12 de Octubre, Madrid, Spain

k Departamento Médico, Amgen S.A., Barcelona, Spain

Read

1384

Times
was read the article

342

Total PDF

1042

Total HTML

Share statistics

 array:23 [
  "pii" => "S2529912320300632"
  "issn" => "25299123"
  "doi" => "10.1016/j.artere.2020.02.004"
  "estado" => "S300"
  "fechaPublicacion" => "2020-09-01"
  "aid" => "528"
  "copyrightAnyo" => "2020"
  "documento" => "article"
  "crossmark" => 1
  "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
  "subdocumento" => "fla"
  "cita" => "Clin Investig Arterioscler. 2020;32:183-92"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "es" => array:20 [
      "pii" => "S0214916820300243"
      "issn" => "02149168"
      "doi" => "10.1016/j.arteri.2020.02.003"
      "estado" => "S300"
      "fechaPublicacion" => "2020-09-01"
      "aid" => "528"
      "copyright" => "The Authors"
      "documento" => "article"
      "crossmark" => 1
      "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
      "subdocumento" => "fla"
      "cita" => "Clin Invest Arterioscl. 2020;32:183-92"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "es" => array:13 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Original</span>"
        "titulo" => "Perfil cl&#237;nico de los pacientes tratados con evolocumab en unidades de l&#237;pidos&#47;medicina interna en Espa&#241;a&#46; Estudio observacional &#40;RETOSS-IMU&#41;"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "183"
            "paginaFinal" => "192"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Clinical profile of patients treated with evolocumab in lipid&#47;internal medicine units of Spain&#46; Observational study &#40;RETOSS-IMU&#41;"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0005"
            "etiqueta" => "Figura 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 960
                "Ancho" => 2504
                "Tamanyo" => 161644
              ]
            ]
            "descripcion" => array:1 [
              "es" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Esquema de la poblaci&#243;n de estudio&#46;</p> <p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">&#42;<span class="elsevierStyleHsp" style=""></span>Un paciente pod&#237;a no ser incluido por m&#225;s de un motivo&#46;</p> <p id="spar0055" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleItalic">Criterios de inclusi&#243;n</span> &#40;CI&#41;&#58;</p> <p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">1&#46; Adultos &#40;&#8805;<span class="elsevierStyleHsp" style=""></span>18<span class="elsevierStyleHsp" style=""></span>a&#241;os&#41; en el momento de inicio del tratamiento con evolocumab&#46;</p> <p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">2&#46; Haber iniciado tratamiento con evolocumab seg&#250;n el criterio m&#233;dico&#44; con independencia del protocolo del estudio&#44; entre el 1 de febrero de 2016 y el 31 de julio de 2017&#46;</p> <p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">3&#46; Haber recibido al menos una dosis de evolocumab &#40;seg&#250;n criterio m&#233;dico&#41; por un especialista en una unidad de medicina interna en Espa&#241;a&#46;</p> <p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">4&#46; Disponer de al menos una determinaci&#243;n de cLDL dentro de las 12<span class="elsevierStyleHsp" style=""></span>semanas anteriores al inicio de evolocumab &#40;&#250;ltimo valor disponible 12<span class="elsevierStyleHsp" style=""></span>semanas previas&#41;&#46;</p> <p id="spar0080" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleItalic">Criterios de exclusi&#243;n</span> &#40;CE&#41;&#58;</p> <p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">1&#46; Haber participado en un estudio con un inhibidor de PCSK9 en las 12 semanas previas al inicio del tratamiento con evolocumab&#46;</p> <p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">2&#46; Haber recibido un inhibidor de PCSK9 en las 12<span class="elsevierStyleHsp" style=""></span>semanas previas al inicio del tratamiento con evolocumab&#46;</p> <p id="spar0095" class="elsevierStyleSimplePara elsevierViewall">3&#46; Haber participado en un estudio cl&#237;nico durante el periodo observacional retrospectivo&#44; es decir&#44; 12<span class="elsevierStyleHsp" style=""></span>semanas antes del inicio del tratamiento con evolocumab o hasta 12<span class="elsevierStyleHsp" style=""></span>semanas despu&#233;s de su inicio&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Llu&#237;s Masana, Jos&#233; L&#243;pez Miranda, Fernando Civeira, Leonardo Reinares, Carlos Guijarro, N&#250;ria Plana, Rafael Cuenca, Demetrio S&#225;nchez, Jos&#233; Luis Hern&#225;ndez, Raimundo Andr&#233;s, Agust&#237;n Blanco, Santiago Villamayor"
            "autores" => array:12 [
              0 => array:2 [
                "nombre" => "Llu&#237;s"
                "apellidos" => "Masana"
              ]
              1 => array:2 [
                "nombre" => "Jos&#233;"
                "apellidos" => "L&#243;pez Miranda"
              ]
              2 => array:2 [
                "nombre" => "Fernando"
                "apellidos" => "Civeira"
              ]
              3 => array:2 [
                "nombre" => "Leonardo"
                "apellidos" => "Reinares"
              ]
              4 => array:2 [
                "nombre" => "Carlos"
                "apellidos" => "Guijarro"
              ]
              5 => array:2 [
                "nombre" => "N&#250;ria"
                "apellidos" => "Plana"
              ]
              6 => array:2 [
                "nombre" => "Rafael"
                "apellidos" => "Cuenca"
              ]
              7 => array:2 [
                "nombre" => "Demetrio"
                "apellidos" => "S&#225;nchez"
              ]
              8 => array:2 [
                "nombre" => "Jos&#233; Luis"
                "apellidos" => "Hern&#225;ndez"
              ]
              9 => array:2 [
                "nombre" => "Raimundo"
                "apellidos" => "Andr&#233;s"
              ]
              10 => array:2 [
                "nombre" => "Agust&#237;n"
                "apellidos" => "Blanco"
              ]
              11 => array:2 [
                "nombre" => "Santiago"
                "apellidos" => "Villamayor"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2529912320300632"
          "doi" => "10.1016/j.artere.2020.02.004"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912320300632?idApp=UINPBA00004N"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0214916820300243?idApp=UINPBA00004N"
      "url" => "/02149168/0000003200000005/v1_202010040619/S0214916820300243/v1_202010040619/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S2529912320300644"
    "issn" => "25299123"
    "doi" => "10.1016/j.artere.2020.03.006"
    "estado" => "S300"
    "fechaPublicacion" => "2020-09-01"
    "aid" => "530"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "Clin Investig Arterioscler. 2020;32:193-9"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original</span>"
      "titulo" => "Effect of clopidogrel vs&#46; aspirin on pro-atherosclerotic NLRP1 inflammasome expression in endothelial cells&#46; ECLOAS study"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "193"
          "paginaFinal" => "199"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Efecto del clopidogrel vs&#46; aspirina en la funci&#243;n de la expresi&#243;n del inflamasoma proateroscler&#243;tico NLRP1 en c&#233;lulas endoteliales&#46; Estudio ECLOAS"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 696
              "Ancho" => 3173
              "Tamanyo" => 150621
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Study phase order&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Silvia Bleda, Joaquin de Haro, Isabel S&#225;nchez, Ilsem Laime, Francisco Acin"
          "autores" => array:5 [
            0 => array:2 [
              "nombre" => "Silvia"
              "apellidos" => "Bleda"
            ]
            1 => array:2 [
              "nombre" => "Joaquin"
              "apellidos" => "de Haro"
            ]
            2 => array:2 [
              "nombre" => "Isabel"
              "apellidos" => "S&#225;nchez"
            ]
            3 => array:2 [
              "nombre" => "Ilsem"
              "apellidos" => "Laime"
            ]
            4 => array:2 [
              "nombre" => "Francisco"
              "apellidos" => "Acin"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0214916820300267"
        "doi" => "10.1016/j.arteri.2020.03.002"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0214916820300267?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912320300644?idApp=UINPBA00004N"
    "url" => "/25299123/0000003200000005/v3_202102250927/S2529912320300644/v3_202102250927/en/main.assets"
  ]
  "en" => array:21 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>"
    "titulo" => "Clinical profile of patients treated with evolocumab in lipid&#47;internal medicine units of Spain&#46; Observational study &#40;RETOSS-IMU&#41;"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "183"
        "paginaFinal" => "192"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Llu&#237;s Masana, Jos&#233; L&#243;pez Miranda, Fernando Civeira, Leonardo Reinares, Carlos Guijarro, N&#250;ria Plana, Rafael Cuenca, Demetrio S&#225;nchez, Jos&#233; Luis Hern&#225;ndez, Raimundo Andr&#233;s, Agust&#237;n Blanco, Santiago Villamayor"
        "autores" => array:12 [
          0 => array:4 [
            "nombre" => "Llu&#237;s"
            "apellidos" => "Masana"
            "email" => array:1 [
              0 => "luis.masana@urv.cat"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "&#42;"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Jos&#233;"
            "apellidos" => "L&#243;pez Miranda"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Fernando"
            "apellidos" => "Civeira"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Leonardo"
            "apellidos" => "Reinares"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Carlos"
            "apellidos" => "Guijarro"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "N&#250;ria"
            "apellidos" => "Plana"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "Rafael"
            "apellidos" => "Cuenca"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "Demetrio"
            "apellidos" => "S&#225;nchez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "aff0035"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "Jos&#233; Luis"
            "apellidos" => "Hern&#225;ndez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "aff0040"
              ]
            ]
          ]
          9 => array:3 [
            "nombre" => "Raimundo"
            "apellidos" => "Andr&#233;s"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "aff0045"
              ]
            ]
          ]
          10 => array:3 [
            "nombre" => "Agust&#237;n"
            "apellidos" => "Blanco"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">j</span>"
                "identificador" => "aff0050"
              ]
            ]
          ]
          11 => array:3 [
            "nombre" => "Santiago"
            "apellidos" => "Villamayor"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">k</span>"
                "identificador" => "aff0055"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:11 [
          0 => array:3 [
            "entidad" => "Servicio de Medicina Interna&#44; Hospital Universitario Sant Joan&#44; IISPV&#44; CIBERDEM&#44; Reus&#44; Tarragona&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Medicina Interna&#44; Hospital Universitario Reina Sof&#237;a&#44; IMIBIC&#44; Universidad de C&#243;rdoba&#44; CIBEROBN&#44; C&#243;rdoba&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Servicio de Medicina Interna&#44; Hospital Universitario Miguel Servet&#44; IIS Arag&#243;n&#44; CIBERCV&#44; Universidad de Zaragoza&#44; Zaragoza&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Servicio de Medicina Interna&#44; Hospital Cl&#237;nico San Carlos&#44; Madrid&#44; Spain"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Servicio de Medicina Interna&#44; Hospital Universitario Fundaci&#243;n Alcorc&#243;n&#44; Universidad Rey Juan Carlos&#44; Alcorc&#243;n&#44; Madrid&#44; Spain"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Servicio de Medicina Interna&#44; Hospital Alto Guadalquivir&#44; And&#250;jar&#44; Ja&#233;n&#44; Spain"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
          6 => array:3 [
            "entidad" => "Servicio de Medicina Interna&#44; Hospital Nuestra Se&#241;ora de Sonsoles&#44; &#193;vila&#44; Spain"
            "etiqueta" => "g"
            "identificador" => "aff0035"
          ]
          7 => array:3 [
            "entidad" => "Unidad de L&#237;pidos y Riesgo Vascular&#44; Servicio de Medicina Interna&#44; Hospital Universitario Marqu&#233;s de Valdecilla-IDIVAL&#46; Santander&#46; Universidad de Cantabria&#44; Santander&#44; Spain"
            "etiqueta" => "h"
            "identificador" => "aff0040"
          ]
          8 => array:3 [
            "entidad" => "Servicio de Medicina Interna&#44; Hospital Universitario Fundaci&#243;n Jim&#233;nez D&#237;az&#44; Madrid&#44; Spain"
            "etiqueta" => "i"
            "identificador" => "aff0045"
          ]
          9 => array:3 [
            "entidad" => "Servicio de Medicina Interna&#44; Hospital Universitario 12 de Octubre&#44; Madrid&#44; Spain"
            "etiqueta" => "j"
            "identificador" => "aff0050"
          ]
          10 => array:3 [
            "entidad" => "Departamento M&#233;dico&#44; Amgen S&#46;A&#46;&#44; Barcelona&#44; Spain"
            "etiqueta" => "k"
            "identificador" => "aff0055"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Perfil cl&#237;nico de los pacientes tratados con evolocumab en unidades de l&#237;pidos&#47;medicina interna en Espa&#241;a&#46; Estudio observacional &#40;RETOSS-IMU&#41;"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:8 [
        "identificador" => "fig0010"
        "etiqueta" => "Fig&#46; 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 1757
            "Ancho" => 2098
            "Tamanyo" => 261431
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0010"
            "detalle" => "Fig&#46; "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">History and cardiovascular risk factors&#46;</p> <p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">AHT&#58; arterial hypertension&#59; CAD&#58; carotid arteriosclerotic disease&#59; CD&#58; cerebrovascular disease&#59; CI&#58; cardiac insufficiency&#59; CV&#58; cardiovascular&#59; CVE&#58; cardiovascular event&#59; DM2&#58; type 2 diabetes mellitus&#59; FH&#58; familial hypercholesterolaemia&#59; He&#58; heterozygote&#59; Ho&#58; homozygote&#59; IMEST&#58; myocardial infarct with raised ST segment&#59; MI&#58; myocardial infarct&#59; Neph&#58; nephropathy&#59; PAD&#58; peripheral arterial disease&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Low density lipoprotein-vehiculated cholesterol &#40;cLDL&#41; is a causal factor of cardiovascular arteriosclerotic disease &#40;CVAD&#41;&#44;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> which originates a high level of morbimortality in our population&#46;<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> As a whole&#44; the set of cardiovascular diseases &#40;CVD&#41; cause approximately one of every three deaths in Spain&#44; slightly more so for women than men&#46;<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3&#44;4</span></a> Treatment with hypocholesterolemiants has helped to reduce cardiovascular &#40;CV&#41; mortality&#46;<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> More specifically&#44; the use of statins &#40;which became widespread in the final decade of the previous century&#41; has given rise to an improved prognosis for CVAD&#46; In the past 30 years&#44; several controlled and randomised studies have supplied very solid scientific evidence for the benefit of hypocholesterolemiant treatment in case of cardiovascular risk &#40;CVR&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1&#44;5</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">The development and clinical availability of PCSK9 inhibitors &#40;PCSK9i&#41; have led to a major advance in the management of hypercholesterolaemia&#46; Evolocumab in particular has shown in multiple phase 2 and 3 clinical trials following its pharmacological development that it reduces cLDL by an average of more than 60&#37;&#44; regardless of the basal hypolipemiant treatment&#46;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> In the FOURIER study&#44; which included more than 27&#44;500 patients with cerebral and peripheral atheramatous vascular cardiac disease&#44; evolocumab reduced the number of events significantly over a period of 2&#46;2 years&#44; confirming that the fall in cLDL induced by the use of evolocumab leads to a lower risk of CV complications&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> These results are fully compatible with those foreseen by the <span class="elsevierStyleItalic">Cholesterol Treatment Trialist Collaboration</span> &#40;CTTC&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> Similar data were obtained in the ODYSSEY OUTCOMES study&#44; which used alirocumab<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> in patients with recent acute coronary syndrome&#46; Likewise&#44; the SPIRE studies with bococizumab<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> gave similar results&#44; although they were interrupted due to the loss of efficacy associated with the development of anti-bococizumab antibodies&#46; The efficacy of the PCSK9i in preventing CV is in line with their hypolipemiant effect and the duration of treatment&#44; according to the results of the CTTC&#46; In the FOURIER study the patients treated with evolocumab attained average cLDL concentrations of 30&#8239;mg&#47;dl&#44; so that it also showed that lower figures than those obtained in previous studies were associated with a greater clinical benefit without increased side effects&#46; These results show that in the prevention of CV the lower the cLDL achieved the better&#44; without to data having been able to set a minimum level of cLDL at which this benefit attenuates or disappears&#46;<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">In spite of the robust scientific evidence about the benefits of reducing cLDL levels to improve the prognosis of patients with high CVR&#44; very few of them attain their therapeutic objectives&#46; Recent fifth edition EUROASPIRE<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> registry data show that 71&#37; of the patients who have suffered a coronary event do not achieve the target cLDL level below 70&#8239;mg&#47;dl&#44; and in 37&#37; of cases they have levels above 100&#8239;mg&#47;dl&#46; Additionally&#44; hypolipemiant treatment in patients with familial hypercholesterolaemia &#40;FH&#41; is a long way from achieving its therapeutic objectives&#44; even in patients followed-up in specialised lipid units&#46;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> The beneficial effects of evolocumab have been demonstrated in population groups at high and very high CVR&#44; achieving very high percentages of patients who attained their therapeutic objectives and even achieved lower figures&#44; associated with greater clinical benefit&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">In spite of the unquestionable hypolipemient efficacy of the PCSK9i drugs&#44; their prescription has been restricted in Spain due to a supposedly better cost-benefit balance&#46; It is only dispensed in hospitals and its use has been restricted to patients with secondary prevention&#44; or those with FH and cLDL levels higher than 100&#8239;mg&#47;dl following treatment with high intensity statins or with the maximum tolerated dose of the same&#46; Additionally&#44; these indications have been modulated by scientific societies such as the <span class="elsevierStyleItalic">Sociedad Espa&#241;ola de Arteriosclerosis</span> &#40;SEA&#41;&#46; In 2016<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> this society issued recommendations that were recently updated on the basis of new scientific evidence that shows the efficacy of PCSK9i drugs in reducing CV events in different groups of patients&#46;<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> The European Medicines Agency recently approved the indication for PCSK9i to reduce CV complications&#44; over and above simply reducing cholesterol&#44; although the Spanish Medicines Agency has not yet updated the report on therapeutic positioning&#46;<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">16&#8211;19</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">The chief aim of this study was to evaluate which type of patients have been treated with evolocumab in the first phase of its clinical availability&#44; in the internal medicine departments that most lipid units in Spain belong to&#44; and its hypolipemiant efficacy within this context&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Patients and methods</span><p id="par0030" class="elsevierStylePara elsevierViewall">This multicentre&#44; retrospective and observational study reviewed the clinical histories of patients who had received evolocumab as part of the usual clinical treatment of hyperlipidaemia in a lipids unit &#47;internal medicine department in Spain&#46; Patients aged &#8805;&#8239;18 years were included who had started treatment with evolocumab prescribed by a doctor in a lipids unit &#47;internal medicine department &#40;regardless of study protocol&#41; from 1 February 2016 to 31 July 2017&#44; who had received at least one dose of evolocumab and who had at least one determination of cLDL within the 12 weeks prior to the start of treatment with evolocumab&#46; Patients who had taken part in a study or had received treatment with a PCSK9i in the 12 previous weeks and&#47;or who had taken part in a clinical trial during the study period were excluded&#46; 20 hospitals took part based on their geographical distribution and level of care&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">The protocol was approved by an ethics committee in each hospital&#44; and all of the patients signed the informed consent document&#46; Clinical data were recorded anonymously from 12 weeks prior to the start of treatment with evolocumab until 12&#8239;&#177;&#8239;4&#8239;weeks after this start&#46; The last analytical parameters measured within the 12 weeks prior to starting treatment with evolocumab were considered to be basal values&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">The indications for starting treatment with evolocumab were recorded&#58; the presence of FH and&#47;or CVD established in the 12 weeks prior to starting the study&#46; The main efficacy variable measured the variation between the previous cLDL levels &#40;during the previous 12 weeks&#41; and subsequent ones &#40;the final determination during the following 12 weeks&#41; after commencing with evolocumab&#46; The following variables were also recorded&#58; age&#44; sex&#44; professional situation&#44; weight&#44; height and body mass index at the start of treatment with evolocumab&#44; family medical history &#40;FH or any other dyslipidaemia&#44; death due to a CV event&#44; diabetes mellitus or hypertension&#41;&#44; personal CVAD &#40;ischemic cardiopathy&#44; cerebrovascular accident&#44; peripheral arteriopathy&#41;&#44; a personal history of dyslipidaemia &#40;FH&#44; combined familial hyperlipidaemia&#44; other types of hypercholesterolaemia and mixed or combined hyperlipidaemia&#41;&#44; diabetes mellitus&#44; hypertension&#44; a history of chronic nephropathy&#44; liver failure&#44; hypothyroidism and smoking&#46; Their previous analytical parameters were determined &#40;the last available figure in the 12 weeks prior to starting treatment with evolocumab and the values subsequent to starting treatment available in the patient&#8217;s clinical history and corresponding to the planned follow-up visits according to clinical practice&#41;&#58; lipid profile &#40;total cholesterol&#44; cLDL&#44; cHDL&#44; triglycerides&#44; non-HDL cholesterol and lipoprotein &#40;a&#41; &#91;Lp&#40;a&#41;&#93;&#46; Additionally&#44; analysis took place to detect whether the therapeutic objectives set by the clinical guides in force at the time &#40;ESC&#47;EAS 2016&#41; for managing hyperlipidaemia had been achieved&#46;<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">Finally&#44; the use of other hypolipemient treatments was recorded&#44; together with any statin intolerance before starting treatment with evolocumab and all of the hypolipemient treatment in the 12 subsequent weeks&#46; Statin intolerance was defined as intolerance to an initial statin at maximum tolerable dose and to a second statin at any dose with an adverse effect attributed to the drug that was resolved when it was withdrawn&#46;</p><p id="par0050" class="elsevierStylePara elsevierViewall">In an exploratory way the hospital and speciality of the doctor who referred the patient to the hospital internal medicine department to start treatment with evolocumab were also determined&#44; together with the number of planned visits in the following months during the first year of treatment and other medical specialities consulted by the patients in the hospital during the study&#44; the hospital in which treatment with evolocumab started and the speciality of the doctor who diagnosed hypercholesterolaemia&#46;</p><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Statistical analysis</span><p id="par0055" class="elsevierStylePara elsevierViewall">A descriptive statistical analysis was performed for all of the variables&#46; The quantitative variables were described using central tendency and dispersion measurements &#40;average&#44; standard deviation &#91;SD&#93;&#44; minimum&#44; 25&#37; quartile &#91;Q1&#93;&#44; median&#44; 75&#37; quartile &#91;Q3&#93; and maximum for non-parametric variables&#41;&#46; For qualitative variables frequency tables and parentages over the total number of responses that could be evaluated were used&#46; In all cases 95&#37; confidence intervals were used &#40;CI 95&#37;&#41;&#46;</p><p id="par0060" class="elsevierStylePara elsevierViewall">The demographic and clinical variables&#44; medical family and personal histories&#44; CVR factors and lipid profile evolution during the study were compared between the following patient subgroups&#58; presence and type of FH&#44; presence and type of diabetes&#44; statin intolerance&#44; basal cLDL ranges&#44; primary and secondary prevention and age groups&#46;</p><p id="par0065" class="elsevierStylePara elsevierViewall">The change in cLDL levels was compared in different visits versus basal levels using the Student t-test for repeated measurements&#46; Levels &#60; &#46;05 were considered to be statistically significant&#46;</p><p id="par0070" class="elsevierStylePara elsevierViewall">An analysis was also carried out of the cLDL levels at the last available measurement after starting treatment with evolocumab&#46;</p><p id="par0075" class="elsevierStylePara elsevierViewall">All of the statistical analyses were performed using version 9&#46;4 of the SAS&#174; System for Windows&#46;</p></span></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Results</span><p id="par0080" class="elsevierStylePara elsevierViewall">A total of 157 patients were recruited&#44; of whom 21 were excluded as they did not meet the selection criteria&#46; The most common reason for exclusion &#40;71&#46;4&#37; of the patients&#41; was that the date their final determination of cLDL was obtained was before the pre-established margin of 12 weeks &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#41;&#46; Finally&#44; 136 patients were included in the evaluation&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0085" class="elsevierStylePara elsevierViewall">The average age &#40;SD&#41; of these 136 patients was 56&#46;6 &#40;11&#46;5&#41; years&#46; 64&#46;0&#37; were men&#44; and their average body mass index was 29&#46;4 &#40;4&#44;8&#41; kg&#47;m<span class="elsevierStyleSup">2</span>&#46; The average cLDL level &#40;SD&#41; before starting treatment with evolocumab was 169&#46;1 &#40;56&#46;6&#41; mg&#47;dl&#46; Their sociodemographic&#44; anthropometric and clinical data are shown in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#46; 75&#46;0&#37; of the patients included were diagnosed as FH&#44; of whom 4 were homozygotic&#46; 51&#46;0&#37; of the patients with FH had previous CVAD&#44; and 36&#46;0&#37; of all the patients were considered to be statin intolerant&#46; These were mainly intolerant of atorvastatin &#40;81&#46;6&#37; of the intolerant patients&#41;&#44; followed by rosuvastatin &#40;57&#46;1&#37;&#41; and simvastatin &#40;38&#46;8&#37;&#41;&#46; The median&#40;Q1-Q3&#41; time from detection of intolerance was 4&#46;0 &#40;2&#46;0-7&#46;9&#41; years&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0090" class="elsevierStylePara elsevierViewall">61&#46;1&#37; of the patients had an established history of CVAD&#46; Their histories and basal CVR factors are shown in <a class="elsevierStyleCrossRef" href="#fig0010">Fig&#46; 2</a>&#46;</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0095" class="elsevierStylePara elsevierViewall">It should be underlined that 75&#46;8&#37; of the patients had cLDL levels higher than 130&#8239;mg&#47;dl&#44; while in 46&#46;4&#37; it was higher than 160&#8239;mg&#47;dl and approximately one of every four patients &#40;26&#46;5&#37;&#41; had levels above 190&#8239;mg&#47;dl &#40;<a class="elsevierStyleCrossRef" href="#fig0015">Fig&#46; 3</a>A&#41;&#46; Their highest basal cLDL levels generally corresponded to patients with FH in primary prevention&#44; and they were lower in patients without FH in secondary prevention&#46; The basal levels of cLDL according to the clinical characteristics of the patients are shown in <a class="elsevierStyleCrossRef" href="#fig0015">Fig&#46; 3</a>B&#46;</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><p id="par0100" class="elsevierStylePara elsevierViewall">At the start of treatment with evolocumab 61&#46;0&#37; of the patients were taking high intensity statins&#44; 60&#46;3&#37; were taking ezetimibe and 49&#46;3&#37; were taking both&#46; The median &#40;Q1-Q3&#41; duration of treatment prior to starting with evolocumab was 3&#46;9 &#40;1&#46;5-7&#46;0&#41; years for the high intensity statins and 4&#46;7 &#40;1&#46;1-10&#46;0&#41; years for ezetimibe&#46; <a class="elsevierStyleCrossRef" href="#fig0020">Fig&#46; 4</a> shows statin treatment intensity distribution &#40;A&#41; and with ezetimibe &#40;B&#41; before starting treatment with evolocumab&#46;</p><elsevierMultimedia ident="fig0020"></elsevierMultimedia><p id="par0105" class="elsevierStylePara elsevierViewall">Treatment with evolocumab produced an average fall of cLDL at 12 weeks of 55&#46;7&#37;&#44; achieving average values of 79&#46;6&#8239;mg&#47;dl&#46; More specifically&#44; 26&#46;9&#37; of the patients attained cLDL levels below 50&#8239;mg&#47;dl&#44; 53&#46;8&#37; reached levels below 70&#8239;mg&#47;dl and 74&#46;4&#37; reached levels below 100&#8239;mg&#47;dl&#46;</p><p id="par0110" class="elsevierStylePara elsevierViewall">The results of the analysis of cLDL levels in patients who had data for their last observation after the start of treatment with evolocumab &#40;n&#8239;&#61;&#8239;110&#41; showed an average fall from basal level of 60&#46;8&#37;&#44; achieving an average value of 74&#46;3&#8239;mg&#47;dl after a median follow-up time of 10&#46;9 weeks&#46;</p><p id="par0115" class="elsevierStylePara elsevierViewall">Likewise&#44; evolocumab also induced falls in non-HDL cholesterol &#40;an average reduction of 49&#46;9&#37;&#41;&#44; without finding a significant change in cHDL levels&#46; There were too few patients with Lp&#40;a&#41; determinations after starting treatment to enable evaluation of the same&#46;</p><p id="par0120" class="elsevierStylePara elsevierViewall">Due to the inclusion criteria&#44; no patient was at target cLDL levels according to their clinical condition&#46; The therapeutic objectives in the study populations &#40;defined as cLDL levels &#60;&#8239;70&#8239;mg&#47;dl or cLDL &#60;&#8239;100&#8239;mg&#47;dl by the 2016 ESC&#47;EAS guides&#41; depending on the CVR situation were achieved by 51&#46;9&#37; of the patients with FH and a CV event&#44; 61&#46;3&#37; of patients with a CV event and no FH and 48&#46;0&#37; of the patients with FH and no previous CV event &#40;<a class="elsevierStyleCrossRef" href="#fig0025">Fig&#46; 5</a>&#41;&#46;</p><elsevierMultimedia ident="fig0025"></elsevierMultimedia><p id="par0125" class="elsevierStylePara elsevierViewall">Basic hypolipemiant treatment was kept stable in the majority of the patients&#44; and only 10&#46;8&#37; suspended their treatment with ezetimibe&#46; The treatment with evolocumab was not suspended in any patient in the studied population&#44; and only one patient increased the interval between doses due to discomfort at the point of injection&#46;</p><p id="par0130" class="elsevierStylePara elsevierViewall">The majority of the patients included in the study were already being managed by lipid units&#47;internal medicine &#40;68&#46;4&#37;&#41;&#44; while 19&#46;1&#37; were detected by primary care and 8&#46;1&#37; were detected by cardiology and referred to the said units&#46; Treatment with evolocumab involved an average of two visits per year for control and renewal of the prescription&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Discussion</span><p id="par0135" class="elsevierStylePara elsevierViewall">This work describes the clinical characteristics of the patients who were prescribed treatment with evolocumab in specialised lipid and CVR units in internal medicine departments in Spain during the initial phase of product commercialisation&#46; As may be expected&#44; the majority of the patients treated in these units had FH &#40;75&#37; of the sample&#41;&#44; bases on two criteria&#58; a very high level of cLDL in the case of primary prevention&#44; or patients who had already suffered an event &#40;51&#37; of the patients with FH&#41;&#46; The second group is composed of patients in secondary prevention without FH&#46; As a whole&#44; 61&#37; of all treatments were prescribed for patients with established CVAD&#44; and for 38&#37; of patients with established CVAD and FH&#46; The fact that the work centred on internal medicine units&#44; the majority of which have SEA accredited lipid units&#44; explains the high proportion of patients with FH&#46; Moreover&#44; as the study took place at the start of availability of the drug&#44; many patients were included who had been monitored historically by the said units who had not attained their objectives and for whom no effective alternative treatment had been available&#46; A clear sign of this is the high percentage of statin-intolerant patients who were included &#40;36&#37;&#41;&#46; It also has to be said that 39&#37; of the patients were not receiving high intensity statins &#40;practically all of them were statin-intolerant&#41;&#44; as well as the high percentage of patients treated with ezetimibe &#40;60&#37;&#41;&#46; It is clear that patients in secondary prevention without FH represent a more numerous group of candidates for therapy with evolocumab&#46; Nevertheless&#44; and unlike the situation with FH&#44; which is usually controlled and followed up in specialised dyslipedaemia units&#44; subjects who have suffered an ischemic CV event are treated by cardiology&#44; neurology or vascular surgery units&#46; Subsequently&#44; these patients are often followed up by primary care doctors&#46; This circumstance may lead to a not insignificant group of these patients not receiving a suitable prescription for PCSK9i&#44; as this drug is dispensed in hospital&#46; Cardiac rehabilitation units&#44; or otherwise lipid&#44; vascular risk or secondary prevention units&#44; play an especially important role&#44; as these are units that determine the moment when PCSK9i is indicated&#46;</p><p id="par0140" class="elsevierStylePara elsevierViewall">It is striking that the average cLDL level at the moment of indication &#40;169&#8239;mg&#47;dl&#41; was clearly above the authorised level for financing of the drug&#44; which stands at 100&#8239;mg&#47;dl&#44; showing that the patients who started treatment clearly fulfilled the indications of the therapeutic positioning report&#46; The fact that the starting point in this cohort is clearly above the recommended treatment thresholds&#44; with almost half of the subjects with cLDL levels &#62;&#8239;160&#8239;mg&#47;dl and 26&#37; &#62;&#8239;190&#8239;mg&#47;dl&#44; may indicate that the first patients who were prescribed evolocumab were patients who had exhausted all of the other therapeutic options in attempting to achieve their cLDL objectives&#46; It also has to be taken into account that the majority of this cohort are patients with FH and&#44; therefore&#44; with very high basal cLDL levels&#46; In fact&#44; the basal cLDL of the patients without FH in secondary prevention was clearly lower&#46; Additionally&#44; given the administrative barriers against prescribing PCSK9i&#44; it is probable that in this initial phase patients with an unquestionable therapeutic indication were selected&#46;</p><p id="par0145" class="elsevierStylePara elsevierViewall">The SEA recently published its latest recommendations for the use of PCSK9i&#44; where it clearly identified the patient profiles which will gain the greatest clinical benefit with these therapies&#46;<span class="elsevierStyleSup">15</span> This may imply the indication of these drugs at lower cLDL levels in patients at especially high risk&#46;</p><p id="par0150" class="elsevierStylePara elsevierViewall">This study in the context of habitual clinical practice confirms the hypolipemiant efficacy of evolocumab&#44; which produced an average fall in initial average cLDL concentrations of 56&#37;&#44; a similar result to that of the clinical trials&#46; In this way&#44; the average levels of cLDL fell below 80&#8239;mg&#47;dl in spite of their high starting point &#40;only 2&#46;2&#37; of the patients had basal levels lower than 100&#8239;mg&#47;dl&#41;&#46; Additionally&#44; 54&#37; attained cLDL levels below 70&#8239;mg&#47;dl&#44; and 27&#37; attained levels below 50&#8239;mg&#47;dl&#46; One highly important datum is the high percentage of patients who attained their therapeutic objectives according to whether or not they had a previous CV event and&#47;or FH&#46; According to the inclusion criteria&#44; no patient had complied with their therapeutic cLDL objectives&#59; the majority of them were a long way from doing so&#46; In spite of this starting point&#44; approximately half of the patients with FH &#40;51&#46;9&#37; with a CV event and 48&#37; without a previous CV event&#41; and 61&#37; of the ones with a CV event without FH achieved their respective therapeutic objectives as set in the 2016 ESC&#47;EAS guides<span class="elsevierStyleSup">20</span> after 12 weeks of treatment with evolocumab&#46;</p><p id="par0155" class="elsevierStylePara elsevierViewall">However&#44; these treatment guides have been updated very recently&#44; and they now specify much stricter therapeutic objectives for the control of cLDL&#46; Patients with CVAD &#40;with or without FH&#41; should attain cLDL concentrations below 55&#8239;mg&#47;dl&#44; while in patients with FH without CVAD the therapeutic objective is to achieve cLDL levels below 70&#8239;mg&#47;dl&#46; Taking these new objectives into account&#44; and in spite of the severity of the patients who started treatment with evolocumab at the start of its commercialisation&#44; 30&#46;8&#37; and 41&#46;9&#37; of the patients with FH and a CV event or a CV event without FH obtained levels below 50&#8239;mg&#47;dl&#44; respectively&#46; On the other hand&#44; of the patients with FH without a previous CV event&#44; 34&#37; of them obtained levels below 70&#8239;mg&#47;dl&#44; indicating that at least one of every 3 patients would accomplish the stricter new objectives in the 2019 ESC&#47;EAS guides&#46;<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">21</span></a></p><p id="par0160" class="elsevierStylePara elsevierViewall">These data show the utility of treatment with evolocumab in achieving therapeutic objectives in high risk patients&#46; Taking into account the recent data from the EUROASPIRE&#8239;5<span class="elsevierStyleSup">12</span> registry&#44; the possibility of increasing hypercholesterolaemia control to this degree in secondary prevention by using evolocumab is unprecedented&#46; Moreover&#44; the results of the FOURIER study&#44; in which more than 87&#37; of the patients were found to achieve cLDL levels &#8804;&#8239;70&#8239;mg&#47;dl after 48 weeks of treatment with evolocumab&#44; also emphasises the usefulness of this drug in achieving therapeutic targets&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a></p><p id="par0165" class="elsevierStylePara elsevierViewall">Although the objectives of this study did not include monitoring pharmacological safety&#44; the high level of adherence to the treatment should be mentioned&#44; given that only one patient discontinued therapy with evolocumab temporarily&#46;</p><p id="par0170" class="elsevierStylePara elsevierViewall">This study has certain limitations&#58; it is a retrospective study limited in observation time&#44; so that it cannot offer data on the impact of the therapy over the longer term&#46; The sample size is small&#44; too&#44; although it is based on strict selection criteria and exhaustive quality control of the data obtained&#46; On the other hand&#44; it centres on lipid units&#47;internal medicine departments&#44; with their particularities&#58; a high frequency of severe dyslipidaemia and statin intolerance&#46; It is probable that the power of evolocumab to attain therapeutic objectives in other contexts would be even greater&#46; In connection with other lipid parameters such as Lp&#40;a&#41;&#44; given the observational nature of the study it was not possible to have sufficiently large samples at different points of the study to be able to evaluate its effects&#46;</p><p id="par0175" class="elsevierStylePara elsevierViewall">There are other analyses of clinical experience with evolocumab in Spain&#44; such as the twin study of this one&#44; the RETOSS-CARDIO study which was undertaken in cardiology units&#46; The efficacy of evolocumab was comparable&#44; as it gave rise to significant falls in cLDL of 58&#37;&#44; although with differences in population type&#44; with more patients with CVD and without FH&#46;<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> Cordero and his collaborators recently published a retrospective multicentre analysis of the use of PCSK9i in 5 Spanish hospitals&#46; They found significant falls in cLDL in approximately 68&#37; and of 41&#37; in comparison with the basal level after using evolocumab and alirocumab&#44; respectively&#46;<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a></p><p id="par0180" class="elsevierStylePara elsevierViewall">This is the first study to report on the clinical profile of the patients treated with evolocumab in lipid units &#47;internal medicine departments in Spain&#46; In this first phase of availability of the therapy patients have been included with a marked diagnosis of severity&#44; very high CVR and very high cLDL levels&#46; Evolocumab has to offer clinical benefits to a population with less extreme indications and therapeutic financing that the one covered by this work&#44; in agreement with the data of the scientific evidence now available&#46;</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Financing</span><p id="par0185" class="elsevierStylePara elsevierViewall">This study was financed by Amgen through an unrestricted subvention&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Conflict of interests</span><p id="par0190" class="elsevierStylePara elsevierViewall">L&#46; Masana has received fees for conferences or scientific consultancy services from Amgen&#44; Sanofi-Regeneron&#44; Mylan&#44; MSD&#44; Daiichi-Sankyo&#44; Danone and Servier&#46;</p><p id="par0195" class="elsevierStylePara elsevierViewall">J&#46; L&#243;pez Miranda has received fees for conferences or scientific consultancy services from Amgen&#44; Sanofi-Regeneron&#44; Ferrer&#44; Esteve and Boeringher&#46;</p><p id="par0200" class="elsevierStylePara elsevierViewall">F&#46; Civeira has received fees for conferences or scientific consultancy services from Amgen&#44; Sanofi-Regeneron&#44; MSD and Ferrer&#46;</p><p id="par0205" class="elsevierStylePara elsevierViewall">L&#46; Reinares participated in the ODYSSEY study as head researcher in the Hospital Cl&#237;nico&#46;</p><p id="par0210" class="elsevierStylePara elsevierViewall">C&#46; Guijarro has received fees for talks&#44; training and consultancy from Amgen&#44; Ferrer&#44; MSD&#44; Pfizer and Sanofi&#46;</p><p id="par0215" class="elsevierStylePara elsevierViewall">N&#46; Plana has received fees for conferences from Amgen&#44; Sanofi-Regeneron and MSD&#46;</p><p id="par0220" class="elsevierStylePara elsevierViewall">R&#46; Cuenca has received fees for conferences from Amgen and Esteve&#46;</p><p id="par0225" class="elsevierStylePara elsevierViewall">J&#46;L&#46; Hern&#225;ndez has received fees for talks or conferences and courses from Amgen&#44; MSD&#44; Sanofi and Esteve&#44; together with research grants from Amgen&#46;</p><p id="par0230" class="elsevierStylePara elsevierViewall">R&#46; Andr&#233;s has received fees for talks or conferences from Amgen and Sanofi&#46;</p><p id="par0235" class="elsevierStylePara elsevierViewall">A&#46; Blanco has received fees for conferences or scientific consultancy services from Amgen&#44; Sanofi-Regeneron and Servier&#46;</p><p id="par0240" class="elsevierStylePara elsevierViewall">S&#46; Villamayor is an Amgen S&#46;A&#46; employee&#46;</p><p id="par0245" class="elsevierStylePara elsevierViewall">D&#46; S&#225;nchez has no conflict of interests to declare&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:12 [
        0 => array:3 [
          "identificador" => "xres1471491"
          "titulo" => "Abstract"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0005"
              "titulo" => "Objective"
            ]
            1 => array:2 [
              "identificador" => "abst0010"
              "titulo" => "Methods"
            ]
            2 => array:2 [
              "identificador" => "abst0015"
              "titulo" => "Results"
            ]
            3 => array:2 [
              "identificador" => "abst0020"
              "titulo" => "Conclusions"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1340093"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres1471492"
          "titulo" => "Resumen"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0025"
              "titulo" => "Objetivo"
            ]
            1 => array:2 [
              "identificador" => "abst0030"
              "titulo" => "M&#233;todos"
            ]
            2 => array:2 [
              "identificador" => "abst0035"
              "titulo" => "Resultados"
            ]
            3 => array:2 [
              "identificador" => "abst0040"
              "titulo" => "Conclusiones"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec1340092"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "Patients and methods"
          "secciones" => array:1 [
            0 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Statistical analysis"
            ]
          ]
        ]
        6 => array:2 [
          "identificador" => "sec0020"
          "titulo" => "Results"
        ]
        7 => array:2 [
          "identificador" => "sec0025"
          "titulo" => "Discussion"
        ]
        8 => array:2 [
          "identificador" => "sec0030"
          "titulo" => "Financing"
        ]
        9 => array:2 [
          "identificador" => "sec0035"
          "titulo" => "Conflict of interests"
        ]
        10 => array:2 [
          "identificador" => "xack515623"
          "titulo" => "Acknowledgements"
        ]
        11 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2019-11-28"
    "fechaAceptado" => "2020-02-24"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1340093"
          "palabras" => array:5 [
            0 => "Evolocumab"
            1 => "Familial hypercholesterolaemia"
            2 => "Arteriosclerotic cardiovascular disease"
            3 => "LDL-C"
            4 => "Lipid unit&#47;internal medicine"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1340092"
          "palabras" => array:5 [
            0 => "Evolocumab"
            1 => "Hipercolesterolemia familiar"
            2 => "Enfermedad cardiovascular arterioscler&#243;tica"
            3 => "c-LDL"
            4 => "Unidades de l&#237;pidos&#47;medicina interna"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:3 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Objective</span><p id="spar0110" class="elsevierStyleSimplePara elsevierViewall">To describe the clinical characteristics&#44; the reasons for initiating therapy&#44; and the effects of treatment in the initial phase of evolocumab availability in Lipid&#47; Internal Medicine Units in Spain&#46;</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Methods</span><p id="spar0115" class="elsevierStyleSimplePara elsevierViewall">Retrospective&#44; observational study&#44; based on the medical records of consecutive patients initiating treatment with evolocumab &#40;from February 2016 to July 2017&#41;&#44; in 20 Internal Medicine Units in Spain&#46; A review was made of the demographic and clinical characteristics of the patients&#44; the lipid lowering treatment&#44; and the evolution of the lipid profiles between 12 weeks pre-initiation and 12&#8239;&#177;&#8239;4 weeks post-initiation of evolocumab&#46;</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0120" class="elsevierStyleSimplePara elsevierViewall">A total of 136 patients were analysed&#44; of whom 64&#46;0&#37; were men&#44; and the mean age &#40;standard deviation&#44; SD&#41; was 56&#46;6 &#40;11&#46;5&#41; years&#46; The large majority &#40;75&#37;&#41; had familial hypercholesterolaemia &#40;FH&#41; &#40;4 homozygous&#41;&#44; and 51&#46;0&#37; of them had suffered at least one cardiovascular event&#46; Atherosclerotic cardiovascular disease &#40;ASCVD&#41; was present in 61&#37; of all patients&#46; At initiation of evolocumab&#44; 61&#46;0&#37; of the patients were taking high-intensity statins&#44; and 60&#46;3&#37; were receiving ezetimibe&#46; The mean &#40;and SD&#41; of LDL-c levels at initiation of evolocumab was 169&#46;1 &#40;56&#46;6&#41; mg&#47;dL&#46; The LDL-c was greater than 160&#8239;mg&#47;dL in 46&#46;4&#37; of patients&#44; and &#8805;190&#8239;mg&#47;dL in 26&#46;5&#37;&#46; During the observation period&#44; evolocumab produced significant reductions in LDL-c of 55&#46;7&#37; &#40;<span class="elsevierStyleItalic">p</span>&#8239;&#60;&#8239;&#46;0001&#41;&#44; achieving mean values of 74&#46;3 mg&#47;dL&#46; At week 12&#44; more than half &#40;53&#46;8&#37;&#41; of patients achieved LDL-c levels &#60;70 mg&#47;dL&#44; and 26&#46;9&#37; &#60;50 mg&#47;dL&#46;</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0125" class="elsevierStyleSimplePara elsevierViewall">In the Lipid&#47;Internal Medicine Units&#44; evolocumab was mainly prescribed in patients with FH&#44; with or without ASCVD&#46; The initial use of evolocumab was in accordance with the guidelines of the Spanish Society of Arteriosclerosis &#40;SEA&#41; of 2016&#44; with LDL-c levels being well above the recommended thresholds for treatment initiation&#46; Evolocumab treatment in clinical practice reduced LDL-C levels by about 55&#37;&#44; a similar reduction to that reported in clinical trials&#46; Most patients achieved LDL-c goals&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Objective"
          ]
          1 => array:2 [
            "identificador" => "abst0010"
            "titulo" => "Methods"
          ]
          2 => array:2 [
            "identificador" => "abst0015"
            "titulo" => "Results"
          ]
          3 => array:2 [
            "identificador" => "abst0020"
            "titulo" => "Conclusions"
          ]
        ]
      ]
      "es" => array:3 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Objetivo</span><p id="spar0130" class="elsevierStyleSimplePara elsevierViewall">Describir las caracter&#237;sticas cl&#237;nicas&#44; las razones del inicio de la terapia y los efectos del tratamiento en la fase inicial de disponibilidad de evolocumab en las unidades de l&#237;pidos&#47;medicina interna de Espa&#241;a&#46;</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">M&#233;todos</span><p id="spar0135" class="elsevierStyleSimplePara elsevierViewall">Estudio retrospectivo&#44; observacional&#44; a partir de las historias cl&#237;nicas de pacientes consecutivos que iniciaron tratamiento con evolocumab &#40;de febrero 2016 a julio 2017&#41;&#44; en 20 unidades de Medicina Interna en Espa&#241;a&#46; Se revisaron las caracter&#237;sticas demogr&#225;ficas y cl&#237;nicas de los pacientes&#44; el tratamiento hipolipemiante y la evoluci&#243;n de los perfiles lip&#237;dicos entre 12 semanas antes y 12&#8239;&#177;&#8239;4 semanas despu&#233;s del inicio de evolocumab&#46;</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0140" class="elsevierStyleSimplePara elsevierViewall">Se analizaron 136 pacientes&#58; el 64&#44;0&#37; eran hombres&#44; la edad media &#40;desviaci&#243;n est&#225;ndar&#44; DE&#41; fue de 56&#44;6 &#40;11&#44;5&#41; a&#241;os&#46; El 75&#44;0&#37; ten&#237;a hipercolesterolemia familiar &#40;HF&#41; &#40;4 homocigotos&#41; de los que el 51&#44;0&#37; hab&#237;an sufrido al menos un evento cardiovascular &#40;CV&#41;&#46; El 61&#44;0&#37; del total de pacientes presentaban enfermedad cardiovascular ateroscler&#243;tica &#40;ECVA&#41;&#46; Al inicio de evolocumab&#44; 61&#44;0&#37; de los pacientes tomaban estatinas de alta intensidad y el 60&#44;3&#37; estaban recibiendo ezetimiba&#46; La media &#40;DE&#41; de los niveles de c-LDL al inicio de evolocumab fue de 169&#44;1 &#40;56&#44;6&#41; mg&#47;dL&#46; En 46&#44;4&#37; de los pacientes el c-LDL fue superior a 160&#8239;mg&#47;dL y en el 26&#44;5&#37; &#8805;190&#8239;mg&#47;dL&#46; Durante el per&#237;odo de observaci&#243;n&#44; evolocumab produjo reducciones significativas de c-LDL del 55&#44;7&#37; &#40;p&#8239;&#60;&#8239;0&#44;0001&#41;&#44; alcanzando unos valores medios de 74&#44;3&#8239;mg&#47;dL&#46; En la semana 12&#44; el 53&#44;8&#37; de los pacientes alcanz&#243; niveles de c-LDL &#60;70&#8239;mg&#47;dL y el 26&#44;9&#37; &#60;50&#8239;mg&#47;dL&#46;</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0145" class="elsevierStyleSimplePara elsevierViewall">En las Unidades de L&#237;pidos&#47;Medicina Interna&#44; evolocumab se prescribi&#243; predominantemente en pacientes con HF con o sin ECVA&#46; El uso inicial de evolocumab se ajust&#243; a las pautas de la Sociedad Espa&#241;ola de Arteriosclerosis &#40;SEA&#41; de 2016&#44; estando las concentraciones de c-LDL claramente por encima de los umbrales recomendados para inicio de tratamiento&#46; El tratamiento con evolocumab en la pr&#225;ctica cl&#237;nica redujo los niveles de cLDL en torno al 55&#37;&#44; cifra comparable a los ensayos cl&#237;nicos permitiendo alcanzar los objetivos terap&#233;uticos en la mayor&#237;a de los casos&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0025"
            "titulo" => "Objetivo"
          ]
          1 => array:2 [
            "identificador" => "abst0030"
            "titulo" => "M&#233;todos"
          ]
          2 => array:2 [
            "identificador" => "abst0035"
            "titulo" => "Resultados"
          ]
          3 => array:2 [
            "identificador" => "abst0040"
            "titulo" => "Conclusiones"
          ]
        ]
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0006">Please cite this article as&#58; Masana L&#44; L&#243;pez Miranda J&#44; Civeira F&#44; Reinares L&#44; Guijarro C&#44; Plana N et al&#46; Perfil cl&#237;nico de los pacientes tratados con evolocumab en unidades de l&#237;pidos&#47;medicina interna en Espa&#241;a&#46; Estudio observacional &#40;RETOSS-IMU&#41;&#46; Clin Investig Arterioscler&#46; 2020&#59;32&#58;183&#8211;192&#46;</p>"
      ]
    ]
    "multimedia" => array:6 [
      0 => array:8 [
        "identificador" => "fig0005"
        "etiqueta" => "Fig&#46; 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 965
            "Ancho" => 2507
            "Tamanyo" => 117894
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0005"
            "detalle" => "Fig&#46; "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Study population&#46;</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">&#42;A patient may be excluded for more than one reason</p> <p id="spar0015" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleItalic">Inclusion criteria</span> &#40;IC&#41;&#58;</p> <p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">1&#46; Adults &#40;&#8805;&#8239;18&#8239;years&#41; at moment of starting treatment with evolocumab&#46;</p> <p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">2&#46; Who started treatment with evolocumab based on medical criteria&#44; regardless of study protocol&#44; from 1 February 2016 and 31 July 2017&#46;</p> <p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">3&#46; Who received at least one dose of evolocumab &#40;based on medical criteria&#41;from a specialist in an internal medicine unit in Spain&#46;</p> <p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">4&#46; With at least one available determination of cLDL in the 12 weeks prior to starting to receive evolocumab &#40;last available level in the 12 previous weeks&#41;&#46;</p> <p id="spar0040" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleItalic">Exclusion criteria</span> &#40;EC&#41;&#58;</p> <p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">1&#46; Having taken part in a study with a PCSK9 inhibitor in the 12 weeks before starting treatment with evolocumab&#46;</p> <p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">2&#46; Having received a PCSK9 inhibitor in the 12 weeks before starting treatment with evolocumab&#46;</p> <p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">3&#46; Having participated in a clinical trial during the retrospective observational period&#44; i&#46;e&#46;&#44; 12 weeks before starting treatment with evolocumab or up to 12 weeks after it commenced&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "fig0010"
        "etiqueta" => "Fig&#46; 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 1757
            "Ancho" => 2098
            "Tamanyo" => 261431
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0010"
            "detalle" => "Fig&#46; "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">History and cardiovascular risk factors&#46;</p> <p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">AHT&#58; arterial hypertension&#59; CAD&#58; carotid arteriosclerotic disease&#59; CD&#58; cerebrovascular disease&#59; CI&#58; cardiac insufficiency&#59; CV&#58; cardiovascular&#59; CVE&#58; cardiovascular event&#59; DM2&#58; type 2 diabetes mellitus&#59; FH&#58; familial hypercholesterolaemia&#59; He&#58; heterozygote&#59; Ho&#58; homozygote&#59; IMEST&#58; myocardial infarct with raised ST segment&#59; MI&#58; myocardial infarct&#59; Neph&#58; nephropathy&#59; PAD&#58; peripheral arterial disease&#46;</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "fig0015"
        "etiqueta" => "Fig&#46; 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr3.jpeg"
            "Alto" => 2327
            "Ancho" => 2181
            "Tamanyo" => 226321
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0015"
            "detalle" => "Fig&#46; "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Basal cLDL levels prior to starting treatment with evolocumab&#46;</p> <p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">CVE&#58; cardiovascular event&#59; FH&#58; familial hypercholesterolaemia&#46;</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "fig0020"
        "etiqueta" => "Fig&#46; 4"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr4.jpeg"
            "Alto" => 1173
            "Ancho" => 2098
            "Tamanyo" => 112328
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0020"
            "detalle" => "Fig&#46; "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">Intensity of treatment with statins &#40;A&#41; and with ezetimibe &#40;B&#41; before starting treatment with evolocumab&#46;</p>"
        ]
      ]
      4 => array:8 [
        "identificador" => "fig0025"
        "etiqueta" => "Fig&#46; 5"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr5.jpeg"
            "Alto" => 1160
            "Ancho" => 2098
            "Tamanyo" => 104849
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0025"
            "detalle" => "Fig&#46; "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">Patients who attained the therapeutic objective&#46;</p> <p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">CVE&#58; cardiovascular event&#59; FH&#58; familial hypercholesterolaemia&#46;</p>"
        ]
      ]
      5 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0030"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0100" class="elsevierStyleSimplePara elsevierViewall">BMI&#58; body mass index&#59; CVE&#58; cardiovascular event&#59; FH&#58; familial hypercholesterolaemia&#59; SD&#58; standard deviation&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Characteristics&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Patients evaluated<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> &#40;n&#8239;&#61;&#8239;136&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Age in years&#44; average &#40;SD&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">56&#46;6 &#40;11&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Male sex&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">87 &#40;64&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Weight in kg&#44; average &#40;SD&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">81&#46;1 &#40;14&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>BMI &#40;kg&#47;m<span class="elsevierStyleSup">2</span>&#41;&#44; average &#40;SD&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">29&#46;4 &#40;4&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Professional situation&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>In work&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">71 &#40;52&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Retired&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">51 &#40;37&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Others&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">14 &#40;10&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Statin intolerance&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">49 &#40;36&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">FH&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">102 &#40;75&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Homozygotic&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;2&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Heterozygotic&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">98 &#40;72&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Patients in secondary prevention&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">83 &#40;61&#46;0&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Patients with FH and secondary prevention&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">52 &#40;38&#46;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#91;0&#44;1&#8211;2&#93;</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#91;0&#44;1&#8211;2&#93;<span class="elsevierStyleItalic">Basal lipid determinations &#40;mg&#47;dl&#41;&#44; average &#40;SD&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Total cholesterol&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">244&#46;8 &#40;62&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>LDL cholesterol&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">169&#46;1 &#40;56&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>HDL cholesterol&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">50&#46;7 &#40;13&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Non-HDL cholesterol&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">189&#46;7 &#40;61&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Triglycerides&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">142&#46;5 &#40;82&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2532146.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Including 3 patients who had no previous CVE and no FH&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0095" class="elsevierStyleSimplePara elsevierViewall">Sociodemographic&#44; anthropometric and basal clinical characteristics&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:23 [
            0 => array:3 [
              "identificador" => "bib0005"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Low-density lipoproteins cause atherosclerotic cardiovascular disease&#46; 1&#46; Evidence from genetic&#44; epidemiologic&#44; and clinical studies&#46; A consensus statement from the European Atherosclerosis Society Consensus Panel"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "B&#46;A&#46; Ference"
                            1 => "H&#46;N&#46; Ginsberg"
                            2 => "I&#46; Graham"
                            3 => "K&#46;K&#46; Ray"
                            4 => "C&#46;J&#46; Packard"
                            5 => "E&#46; Bruckert"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/eurheartj/ehx144"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Heart J&#46;"
                        "fecha" => "2017"
                        "volumen" => "38"
                        "paginaInicial" => "2459"
                        "paginaFinal" => "2472"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28444290"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0010"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Instituto Nacional de Estad&#237;stica &#91;Internet&#93;&#46; Defunciones seg&#250;n la Causa de Muerte 2016&#46; &#91;accessed 8 Apr 2019&#93;&#46; Available from&#58; http&#58;&#47;&#47;www&#46;ine&#46;es&#47;jaxi&#47;Tabla&#46;htm&#63;path&#61;&#47;t15&#47;p417&#47;a2016&#47;l0&#47;&#38;file&#61;01003&#46;px&#38;L&#61;0&#46;8&#46;"
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0015"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "European Heart Network&#46; CVD Statistics &#91;Internet&#93;&#46; &#91;accessed 28 May 2019&#93;&#46; Available from&#58; http&#58;&#47;&#47;www&#46;ehnheart&#46;org&#47;cvd-statistics&#46;html&#46;"
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0020"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Contribuciones de la mortalidad cardiovascular a la esperanza de vida de la poblaci&#243;n espa&#241;ola de 1980 a 2009"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "JM Garc&#237;a-Gonz&#225;lez"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.recesp.2013.05.014"
                      "Revista" => array:6 [
                        "tituloSerie" => "Rev Esp Cardiol&#46;"
                        "fecha" => "2013"
                        "volumen" => "66"
                        "paginaInicial" => "848"
                        "paginaFinal" => "853"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24773991"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0025"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cholesterol lowering with statin drugs&#44; risk of stroke&#44; and total mortality&#46; An overview of randomized trials"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "P&#46;R&#46; Hebert"
                            1 => "J&#46;M&#46; Gaziano"
                            2 => "K&#46;S&#46; Chan"
                            3 => "C&#46;H&#46; Hennekens"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jama.1997.03550040069040"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA"
                        "fecha" => "1997"
                        "volumen" => "278"
                        "paginaInicial" => "313"
                        "paginaFinal" => "321"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9228438"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Sabatine"
                            1 => "R&#46; Giugliano"
                            2 => "S&#46; Wiviott"
                            3 => "F&#46; Raal"
                            4 => "D&#46; Blom"
                            5 => "J&#46; Robinson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1500858"
                      "Revista" => array:7 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2015"
                        "volumen" => "372"
                        "paginaInicial" => "1500"
                        "paginaFinal" => "1509"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25773607"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0168827814005492"
                          "estado" => "S300"
                          "issn" => "01688278"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Sabatine"
                            1 => "R&#46; Giugliano"
                            2 => "A&#46; Keech"
                            3 => "N&#46; Honarpour"
                            4 => "S&#46; Wiviott"
                            5 => "S&#46; Murphy"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1615664"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2017"
                        "volumen" => "376"
                        "paginaInicial" => "1713"
                        "paginaFinal" => "1722"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28304224"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of cholesterol-lowering treatment&#58; prospective meta-analysis of data from 90&#44;056 participants in 14 randomised trials of statins"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; Baigent"
                            1 => "A&#46; Keech"
                            2 => "P&#46; Kearney"
                            3 => "L&#46; Blackwell"
                            4 => "G&#46; Buck"
                            5 => "C&#46; Pollicino"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(05)67394-1"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2005"
                        "volumen" => "366"
                        "paginaInicial" => "1267"
                        "paginaFinal" => "1278"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16214597"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46; Schwartz"
                            1 => "P&#46; Steg"
                            2 => "M&#46; Szarek"
                            3 => "D&#46; Bhatt"
                            4 => "V&#46; Bittner"
                            5 => "R&#46; Diaz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1801174"
                      "Revista" => array:7 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2018"
                        "volumen" => "379"
                        "paginaInicial" => "2097"
                        "paginaFinal" => "2107"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30403574"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0016508520303620"
                          "estado" => "S300"
                          "issn" => "00165085"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46; Ridker"
                            1 => "J&#46; Revkin"
                            2 => "P&#46; Amarenco"
                            3 => "R&#46; Brunell"
                            4 => "M&#46; Curto"
                            5 => "F&#46; Civeira"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1701488"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med&#46;"
                        "fecha" => "2017"
                        "volumen" => "376"
                        "paginaInicial" => "1527"
                        "paginaFinal" => "1539"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28304242"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab&#58; a prespecified secondary analysis of the FOURIER trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46; Giugliano"
                            1 => "T&#46; Pedersen"
                            2 => "J&#46; Park"
                            3 => "Z&#46; Gaciong"
                            4 => "R&#46; Ceska"
                            5 => "K&#46; Toth"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(17)32290-0"
                      "Revista" => array:5 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2017"
                        "volumen" => "390"
                        "paginaInicial" => "1962"
                        "paginaFinal" => "1971"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries&#58; Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46; Kotseva"
                            1 => "G&#46; De Backer"
                            2 => "D&#46; De Bacquer"
                            3 => "L&#46; Ryd&#233;n"
                            4 => "A&#46; Hoes"
                            5 => "D&#46; Grobbee"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/2047487318825350"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur J Prev Cardiol"
                        "fecha" => "2019"
                        "volumen" => "26"
                        "paginaInicial" => "824"
                        "paginaFinal" => "835"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30739508"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Consecuci&#243;n del objetivo terap&#233;utico del colesterol de las lipoprote&#237;nas de baja densidad en las unidades de l&#237;pidos y riesgo vascular de la Sociedad Espa&#241;ola de Arteriosclerosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "J&#46; Pedro-Botet"
                            1 => "J&#46;M&#46; Mostaza"
                            2 => "X&#46; Pint&#243;"
                            3 => "JR Banegas"
                            4 => "en nombre del grupo de investigadores EDICONDIS-ULISEA"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.arteri.2013.07.006"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Investig Arterioscler&#46;"
                        "fecha" => "2013"
                        "volumen" => "25"
                        "paginaInicial" => "155"
                        "paginaFinal" => "163"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24041476"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Documento de consenso de la Sociedad Espa&#241;ola de Arteriosclerosis sobre las indicaciones de los inhibidores de la PCSK9"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Masana"
                            1 => "J&#46; Acaso"
                            2 => "F&#46; Civeira"
                            3 => "J&#46; Pedro-Botet"
                            4 => "P&#46; Valdivielso"
                            5 => "C&#46; Guijarro"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.arteri.2016.02.001"
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Invest Arterioscl&#46;"
                        "fecha" => "2016"
                        "volumen" => "28"
                        "paginaInicial" => "164"
                        "paginaFinal" => "165"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Indicaciones de los inhibidores de PCSK9 en la pr&#225;ctica cl&#237;nica&#46; Recomendaciones de la Sociedad Espa&#241;ola de Arteriosclerosis &#40;SEA&#41;&#44; 2019"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;F&#46; Ascaso"
                            1 => "F&#46; Civeira"
                            2 => "C&#46; Guijarro"
                            3 => "J&#46; L&#243;pez Miranda"
                            4 => "L&#46; Masana"
                            5 => "J&#46;M&#46; Mostaza"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.arteri.2019.04.002"
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Invest Arterioscl&#46;"
                        "fecha" => "2019"
                        "volumen" => "31"
                        "paginaInicial" => "128"
                        "paginaFinal" => "139"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Agencia Espa&#241;ola de Medicamentos y Productos Sanitarios &#91;Internet&#93;&#46; Informe de Posicionamiento Terap&#233;utico de evolocumab &#40;Repatha&#174;&#41; en hipercolesterolemia&#46; 2016 &#91;accessed 19 Apr 2019&#93;&#46; Available from&#58; https&#58;&#47;&#47;www&#46;aemps&#46;gob&#46;es&#47;medicamentosUsoHumano&#47;informesPublicos&#47;docs&#47;IPT-evolocumab-repatha&#46;pdf&#46;"
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Agencia Espa&#241;ola de Medicamentos y Productos Sanitarios &#91;Internet&#93;&#46; Informe de Posicionamiento Terap&#233;utico de alirocumab &#40;Praluent&#174;&#41; en hipercolesterolemia&#46; 2016 &#91;accessed 19 Apr 2019&#93;&#46; Available from&#58; https&#58;&#47;&#47;www&#46;aemps&#46;gob&#46;es&#47;medicamentosUsoHumano&#47;informesPublicos&#47;docs&#47;IPT-alirocumab-Praluent-hipercolesterolemia&#46;pdf&#46;"
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "European Medicines Agency &#91;Internet&#93;&#46; EMA&#47;233126&#47;2018&#46; Committee for Medicinal Products for Human Use &#40;CHMP&#41;&#46; Assessment report&#58; Repatha&#46; 2018 &#91;accessed 19 Apr 2019&#93;&#46; Available from&#58; https&#58;&#47;&#47;www&#46;ema&#46;europa&#46;eu&#47;en&#47;documents&#47;variation-report&#47;repatha-h-c-3766-ii-0017-g-epar-assessment-report-variation&#95;en&#46;pdf&#46;"
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "European Medicines Agency &#91;Internet&#93;&#46; EMA&#47;CHMP&#47;44606&#47;2019&#46; Committee for Medicinal Products for Human Use &#40;CHMP&#41;&#46; Summary of opinion &#40;post authorisation&#41;&#58; Praluent &#40;alirocumab&#41;&#46; 2019 &#91;accessed 19 Apr 2019&#93;&#46; Available from&#58; https&#58;&#47;&#47;www&#46;ema&#46;europa&#46;eu&#47;en&#47;documents&#47;smop&#47;chmp-post-authorisation-summary-positive-opinion-praluent-ii-42&#95;en&#46;pdf&#46;"
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "2016 ESC&#47;EAS Guidelines for the Management of Dyslipidaemias"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46;L&#46; Catapano"
                            1 => "I&#46; Graham"
                            2 => "G&#46; De Backer"
                            3 => "O&#46; Wiklund"
                            4 => "M&#46;J&#46; Chapman"
                            5 => "H&#46; Drexel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/eurheartj/ehw272"
                      "Revista" => array:7 [
                        "tituloSerie" => "Eur Heart J&#46;"
                        "fecha" => "2016"
                        "volumen" => "37"
                        "paginaInicial" => "2999"
                        "paginaFinal" => "3058"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27567407"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S2468125320300571"
                          "estado" => "S300"
                          "issn" => "24681253"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0105"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "2019 ESC&#47;EAS Guidelines for the management of dyslipidaemias&#58; lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology &#40;ESC&#41; and European Atherosclerosis Society &#40;EAS&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "F&#46; Mach"
                            1 => "C&#46; Baigent"
                            2 => "A&#46;L&#46; Catapano"
                            3 => "K&#46;C&#46; Koskinas"
                            4 => "M&#46; Casula"
                            5 => "L&#46; Badimon"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/eurheartj/ehz455"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Heart J"
                        "fecha" => "2020"
                        "volumen" => "41"
                        "paginaInicial" => "111"
                        "paginaFinal" => "188"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31504418"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0110"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Barrios V&#46;&#44; Escobar C&#46;&#44; Arrarte V&#46;&#44; Rold&#225;n C&#46; Primer registro nacional de evolocumab en la pr&#225;ctica cl&#237;nica en unidades de cardiolog&#237;a en Espa&#241;a&#46; Estudio RETOSS-CARDIO&#46; Rev Esp Cardiol &#91;Internet&#93;&#46; &#91;accessed 7 Feb 2020&#93;&#59; Available from&#58; http&#58;&#47;&#47;www&#46;revespcardiol&#46;org&#47;es-primer-registro-nacional-evolocumab-practica-avance-S0300893219305536&#46;"
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0115"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Experiencia inicial en la pr&#225;ctica cl&#237;nica con los inhibidores PCSK&#8211;9 para las indicaciones actuales de financiaci&#243;n en Espa&#241;a &#124; Revista Espa&#241;ola de Cardiolog&#237;a &#91;Internet&#93;&#46; &#91;accessed 7 Feb 2020&#93;&#46; Available from&#58; https&#58;&#47;&#47;www&#46;revespcardiol&#46;org&#47;es-experiencia-inicial-practica-clinica-con-articulo-S0300893219301629&#63;&#46;"
                ]
              ]
            ]
          ]
        ]
      ]
    ]
    "agradecimientos" => array:1 [
      0 => array:4 [
        "identificador" => "xack515623"
        "titulo" => "Acknowledgements"
        "texto" => "<p id="par0250" class="elsevierStylePara elsevierViewall">We would like to thank the medical department of Amgen for the design of the study in collaboration with the national coordinator of the same and the main researchers &#40;scientific committee&#41; in each hospital&#46;</p><p id="par0255" class="elsevierStylePara elsevierViewall">The manuscript was prepared by the scientific coordinator of the study and validated by the scientific committee&#44; with the help of TFS S&#46;L&#46;&#44; which monitored the study&#44; undertook the statistical analysis and revised the text of the manuscript&#46;</p>"
        "vista" => "all"
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/25299123/0000003200000005/v3_202102250927/S2529912320300632/v3_202102250927/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "64744"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Originals"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/25299123/0000003200000005/v3_202102250927/S2529912320300632/v3_202102250927/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912320300632?idApp=UINPBA00004N"
]

Article information

ISSN: 25299123
Original language: English

DOI:10.1016/j.artere.2020.02.004

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	6	1	7
2024 October	38	9	47
2024 September	40	20	60
2024 August	25	14	39
2024 July	13	6	19
2024 June	9	4	13
2024 May	18	3	21
2024 April	48	4	52
2024 March	155	9	164
2024 February	11	9	20
2024 January	15	8	23
2023 December	32	22	54
2023 November	32	10	42
2023 October	26	5	31
2023 September	32	10	42
2023 August	16	5	21
2023 July	17	8	25
2023 June	19	7	26
2023 May	11	12	23
2023 April	19	7	26
2023 March	17	4	21
2023 February	15	5	20
2023 January	15	4	19
2022 December	19	7	26
2022 November	18	13	31
2022 October	21	14	35
2022 September	27	6	33
2022 August	24	5	29
2022 July	19	7	26
2022 June	13	5	18
2022 May	21	7	28
2022 April	19	12	31
2022 March	14	14	28
2022 February	18	2	20
2022 January	33	4	37
2021 December	20	6	26
2021 November	20	8	28
2021 October	25	9	34
2021 September	12	9	21
2021 August	12	3	15
2021 July	12	4	16
2021 June	20	1	21
2021 May	17	5	22
2021 April	18	6	24
2021 March	10	7	17
2020 November	1	2	3

Show all

Indexed in:

Follow us:

Subscribe:

Statistics

Indexed in:

Follow us:

Subscribe:

Statistics

Subscribe to our newsletter